

09/889733 09/14/01
JC03 Rec'd PCT/PTO 20 JUL 2001

FORM PTO-1390 (REV 11-2000)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 117-358
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/889733
INTERNATIONAL APPLICATION NO. PCT/GB00/00226	INTERNATIONAL FILING DATE 26 January 2000	PRIORITY DATE CLAIMED 26 January 1999
TITLE OF INVENTION DIMETHYLARGININE DIMETHYLAMINOHYDROLASES (AS AMENDED)		
APPLICANT(S) FOR DO/EO/US VALLANCE et al.		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
- ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
- ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
- ☒ The U.S. has been elected by the expiration of 19 months from the priority date (Article 31).
A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
- ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has **NOT** expired.
 - d. ☐ have not been made and will not be made.
- 8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- 9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- 10. ☐ A English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 To 20 below concern document(s) or information included:

- 11. ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
- 12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
- 13. ☒ A FIRST preliminary amendment.
- 14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
- 15. ☐ A substitute specification.
- 16. ☐ A change of power of attorney and/or address letter.
- 17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
- 18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
- 19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
- 20. ☒ Other items or information. Sequence Listing (19 pages)

MC18 Rec'd PTO 20 JUL 2001

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/889733		INTERNATIONAL APPLICATION NO. PCT/GB00/00226		ATTORNEY'S DOCKET NUMBER 117-358	
21. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5)): -- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1000.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....\$860.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO\$710.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$	860.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).				\$	130.00
CLAIMS		NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	25	-20 =	5	X	\$18.00
Independent Claims	12	-3 =	9	X	\$80.00
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)				\$270.00	\$ 0.00
TOTAL OF ABOVE CALCULATIONS =				\$	1800.00
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.					0.00
SUBTOTAL =				\$	1800.00
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).					0.00
TOTAL NATIONAL FEE =				\$	1800.00
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property				+	\$ 0.00
Fee for Petition to Revive Unintentionally Abandoned Application (\$1240.00 - Small Entity = \$620.00)				\$	0.00
TOTAL FEES ENCLOSED =				\$	1800.00
				Amount to be: refunded	\$
				Charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$1800.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed. d. <input checked="" type="checkbox"/> The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.					
NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000					
				<i>Mary J. Wilson</i> SIGNATURE	
				Mary J. Wilson NAME	
				32,955 July 20, 2001 REGISTRATION NUMBER Date	

09889733 091401
09/889733
JCTO rec'd PCT/PTO 20 JUL 2001

#8
fre
a

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

VALLANCE et al.

Atty. Ref.: 117-358

Serial No. Unknown

Group:

Filed: July 20, 2001

Examiner:

For: DIMETHYLARGININE DIMETHYLAMINOHYDROLASES (AS AMENDED)

* * * * *

July 20, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

In order to place the above-identified application in better condition for examination,
please amend the application as follows:

IN THE CLAIMS

Please cancel claims 1-45 without prejudice or disclaimer.

Please add claims 46-70 as follows:

46. (New) An isolated polynucleotide which:

(a) encodes a polypeptide that has the properties of a methylarginase, which
polynucleotide is selected from the group consisting of:

- (1) the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11;
- (2) a fragment of a sequence defined in (1);
- (3) a sequence which hybridises selectively to the complement of a sequence
defined in (1) or (2); and

- (4) a sequence that is degenerate as a result of the genetic code with respect to a sequence defined in (1), (2) or (3); or
- (b) is a sequence complementary to a polynucleotide defined in (a).

47. (New) An isolated polynucleotide according to claim 46 which is a DNA sequence.

48. (New) An isolated polynucleotide which encodes an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 19 and 12.

49. (New) An isolated polypeptide which has methylarginase activity and which comprises a sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10 and 12, a sequence substantially homologous thereto or a fragment of either said sequence.

50. (New) A vector incorporating a polynucleotide which

- (a) encodes a polypeptide that has the properties of a methylarginase, which polynucleotide is selected from the group consisting of:
 - (1) the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11;
 - (2) a fragment of a sequence defined in (1);
 - (3) a sequence which hybridises selectively to the complement of a sequence defined in (1) or (2); and
 - (4) a sequence that is degenerate as a result of the genetic code with respect to a sequence defined in (1), (2) or (3); or
- (b) is a sequence complementary to a polynucleotide defined in (a).

51. (New) A vector according to claim 50, which is an expression vector.

52. (New) A cell harbouring a polynucleotide which:

- (a) encodes a polypeptide that has the properties of a methylarginase, which polynucleotide is selected from the group consisting of:
 - (1) the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11;
 - (2) a fragment of a sequence defined in (1);
 - (3) a sequence which hybridises selectively to the complement of a sequence defined in (1) or (2); and
 - (4) a sequence that is degenerate as a result of the genetic code with respect to a sequence defined in (1), (2) or (3); or

(b) is a sequence complementary to a polynucleotide defined in (a),
a polypeptide which has methylarginase activity and which comprises a sequence
selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10 and 12, a sequence substantially
homologous thereto or a fragment of either said sequence or
a vector incorporating a said polynucleotide.

53. (New) A process for the preparation of a polypeptide which has methylarginase
activity, which process comprises the steps of cultivating a host cell harbouring an expression
vector according to claim 51 under conditions to provide for expression of the said polypeptide,
and recovering the expressed polypeptide.

54. (New) An antibody capable of binding
a polypeptide encoded by a polynucleotide which:

- (a) encodes a polypeptide that has the properties of a methylarginase, which
polynucleotide is selected from the group consisting of:
- (1) the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11;
 - (2) a fragment of a sequence defined in (1);
 - (3) a sequence which hybridises selectively to the complement of a sequence
defined in (1) or (2); and
 - (4) a sequence that is degenerate as a result of the genetic code with respect to
a sequence defined in (1), (2) or (3); or

(b) is a sequence complementary to a polynucleotide defined in (a) or
a polypeptide which has methylarginase activity and which comprises a sequence
selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10 and 12, a sequence substantially
homologous thereto or a fragment of either said sequence.

55. (New) A non-human animal which is not capable of expressing or is not capable of
expressing an active form of one or more isoforms of methylarginase.

56. (New) A non-human animal according to claim 55, wherein the methylarginase
isoform is a dimethylarginine dimethylaminohydrolase I (DDAHI) or
dimethylaminohydrolase II (DDAHI).

57. (New) A non-human animal according to claim 55 which is a transgenic animal.

58. (New) A non-human animal according to claim 57 which is a mouse.

59. (New) A modulator of methylarginase activity and/or expression.

60. (New) A modulator according to claim 59, which is an inhibitor of methylarginase activity and/or expression.

61. (New) A modulator according to claim 59, which is an activator of methylarginase activity and/or expression.

62. (New) A modulator according to claim 60, which is an inhibitor of a bacterial methylarginase.

63. (New) A modulator according to claim 59, wherein the methylarginase is a DDAH I or DDAH II.

64. (New) A method for identifying a modulator of methylarginase activity and/or expression, the method comprising the steps of:

- a'
- (i) contacting a test substance and a polynucleotide which:
 - (a) encodes a polypeptide that has the properties of a methylarginase, which polynucleotide is selected from the group consisting of:
 - (1) the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11;
 - (2) a fragment of a sequence defined in (1);
 - (3) a sequence which hybridises selectively to the complement of a sequence defined in (1) or (2); and
 - (4) a sequence that is degenerate as a result of the genetic code with respect to a sequence defined in (1), (2) or (3); or
 - (b) is a sequence complementary to a polynucleotide defined in (a), a polypeptide which has methylarginase activity and which comprises a sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10 and 12, a sequence substantially homologous thereto or a fragment of either said sequence, a vector incorporating a said polynucleotide or a cell harbouring a said polynucleotide, polypeptide or vector under conditions that would permit methylarginase activity in the absence of the test substance; and
 - (ii) determining thereby whether the said substance modulates the activity and/or expression of methylarginase.

65. (New) A method according to claim 64 further comprising the step of formulating a modulator identified in step (ii) with a pharmaceutically acceptable carrier or diluent.

66. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or diluent and

a polynucleotide which:

(a) encodes a polypeptide that has the properties of a methylarginase, which polynucleotide is selected from the group consisting of:

- Q¹
- (1) the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11;
 - (2) a fragment of a sequence defined in (1);
 - (3) a sequence which hybridises selectively to the complement of a sequence defined in (1) or (2); and
 - (4) a sequence that is degenerate as a result of the genetic code with respect to a sequence defined in (1), (2) or (3); or

(b) is a sequence complementary to a polynucleotide defined in (a),

a polypeptide which has methylarginase activity and which comprises a sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10 and 12, a sequence substantially homologous thereto or a fragment of either said sequence,

an expression vector incorporating a said polynucleotide or
a modulator of methylarginase activity and/or expression.

67. (New) A method of treating a human or animal suffering from a condition selected from the group consisting of hyperlipidaemia, renal failure, hypertension, restenosis after angioplasty, atherosclerosis, complications of heart failure, schizophrenia, multiple sclerosis and cancer, which method comprises the step of administering to the host a therapeutically effective amount of

a polypeptide which has methylarginase activity and which comprises a sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10 and 12, a sequence substantially homologous thereto or a fragment of either said sequence,

an expression vector incorporating a polynucleotide which:

(a) encodes a polypeptide that has the properties of a methylarginase, which polynucleotide is selected from the group consisting of:

- (1) the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11;

- (2) a fragment of a sequence defined in (1);
 - (3) a sequence which hybridises selectively to the complement of a sequence defined in (1) or (2); and
 - (4) a sequence that is degenerate as a result of the genetic code with respect to a sequence defined in (1), (2) or (3); or
- (b) is a sequence complementary to a polynucleotide defined in (a), or a modulator which is an inhibitor of methylarginase activity and/or expression.

Q 1
68. (New) A method of treating a human or animal suffering from a condition selected from the group consisting of ischaemia-reperfusion injury of the brain or heart, cancer, lethal hypotension in severe inflammatory conditions such as septic shock or multi-organ failure, or local and systemic inflammatory disorders including arthritis, skin disorders, inflammatory cardiac disease, migraine and a bacterial infection, which method comprises the step of administering to the host a therapeutically effective amount of a modulator which is an inhibitor of methylarginase activity and/or expression.

69. (New) A method according to claim 68, which further comprises administering to the host a methylarginine.

70. (New) A method according to claim 69, wherein the methylarginine is L-NMMA.

REMARKS

The above amendments are made to place the claims in a more traditional format.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____

Mary J. Wilson

Mary J. Wilson
Reg. No. 32,955

MJW:ms
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

SCREEN METHOD

PTO/PCT Rec'd 20 JUL 2001

Technical field of the invention

This invention relates to methods of screening for compounds which
5 specifically regulate different isoforms of dimethylarginine dimethylaminohydrolase.

Background of the invention

Arginine residues in proteins are methylated by a family of Protein arginine
N-methyltransferases (PRMTs). These enzymes catalyze the methylation of
10 guanidino nitrogens of arginine to produce N^G monomethyl-L-arginine (L-NMMA),
N^GN^G dimethyl-L-arginine (asymmetric dimethylarginine; ADMA) and N^GN^G
dimethylarginine (symmetric dimethylarginine; SDMA). Proteolysis of proteins
containing these residues releases free methylarginines. Although the biological role
of methylarginine residues is unclear, free L-NMMA and ADMA, but not SDMA,
15 are inhibitors of all three isoforms of nitric oxide synthase (NOS) and might alter
NOS activity in health or disease.

Free methylarginines are found in cell cytosol, plasma and tissues and their
concentrations differ between tissues and between regions within a single tissue or
organ. Elevated concentrations of ADMA have been detected in endothelial cells
20 repopulating blood vessels damaged by balloon injury, in the plasma of patients or
experimental animals with hyperlipidaemia, renal failure or atherosclerosis, and in
patients with schizophrenia or multiple sclerosis. Altered biosynthesis of nitric oxide
(NO) has been implicated in the pathogenesis of all of these conditions and it is
possible that the accumulation of endogenous ADMA underlies the inhibition of NO
25 generation.

The production of methylarginines is probably an obligatory step in protein
turnover, and rates of production may show tissue specific and temporal variations.
However, L-NMMA and ADMA, but not SDMA, are actively metabolised to
citrulline and methylamines by the action of dimethylarginine
30 dimethylaminohydrolase (DDAH). Certain tissues which express NOSs also appear
to express DDAH. Pharmacological inhibition of DDAH increases the concentration

of ADMA in endothelial cells and inhibits NO-mediated endothelium-dependent relaxation of blood vessels. These observations suggest that DDAH activity ensures that the local concentration of ADMA does not normally rise sufficiently to affect NO generation, and that changes in DDAH activity could actively alter NOS activity.

Summary of the invention

The present invention is based on our finding that humans express two functionally active methylarginases, which we have called DDAHI and DDAHII. We have cloned the polynucleotides that encode DDAHI and DDAHII isoforms and have studied the expression patterns of these two methylarginases via RNA blotting. These experiments revealed that DDAHI has a tissue distribution in humans which is similar to that of the neuronal isoform of nitric oxide synthase (nNOS), whilst DDAHII is highly expressed in vascular tissues which also express endothelial (eNOS).

Furthermore, we have shown that DDAHII is expressed in immune tissues and is located to chromosome 6p21.3. That chromosomal locus has been implicated in susceptibility to several diseases, including rheumatoid arthritis and insulin-dependent diabetes mellitus (IDDM) and the altered production of nitric oxide has been implicated in the pathology of both of those diseases.

Our data provide evidence that methylarginine concentration is actively regulated in cells that express NOS and further, suggest that there is a mechanism of regulation of NOS whereby different isoforms of NOS are specifically regulated as methylarginine concentrations are modulated by the action of specific DDAH enzymes.

DDAHI and DDAHII therefore provide new targets for the isolation of substances which can specifically modulate the activity of particular NOS isoforms or other arginine utilising enzymes through specific interaction with particular DDAH isoforms. Such substances may be useful in the treatment of diseases in which abnormal levels of methylarginines and/or nitric oxide are implicated.

Furthermore, we have found that the human DDAHI and DDAHII share significant homology with bacterial arginine deiminases. Arginine deiminases have

only been described in prokaryotic organisms and the primitive eukaryote *Giardia intestinalis*. Arginine deiminase catalyse the hydrolysis of arginine to ammonia and citrulline in a reaction that closely resembles the hydrolysis of methylarginine to methylamine and citrulline catalysed by DDAH.

5 We have isolated DDAH sequences from three species of bacteria and an arginine deiminase sequence from *P. aeruginosa*. The enzymes encoded by these sequences can be expressed at high levels and large quantities of the expressed enzyme can be recovered. Thus we have identified an excellent source of enzymes which can be used to identify compounds capable of modulating the activity of
10 DDAH enzymes.

According to the present invention there is thus provided a polynucleotide which:

- 15 (a) encodes a polypeptide that has the properties of a methylarginase, which polynucleotide is selected from:
- (1) the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11;
 - (2) a sequence which hybridises selectively to the complement of a sequence defined in (1); and
 - (3) a sequence that is degenerate as a result of the genetic code
20 with respect to a sequence defined in (1) or (2); or
- (b) is a sequence complementary to a polynucleotide defined in (a).

The invention also provides:

- 25 - a polypeptide which has methylarginase activity and which comprises the sequence set out in SEQ ID NO: 2, 4, 6, 8, 10 or 12, a sequence substantially homologous thereto or a fragment of either said sequence.
- a vector incorporating a polynucleotide of the invention.
- 30 - a cell harbouring a polynucleotide, a peptide or a vector of the invention.

- an antibody capable of binding a polypeptide encoded by a polynucleotide of the invention or a polypeptide of the invention.
- a non-human animal which is not capable of expressing or is not capable of expressing an active form of one or more isoforms of methylarginase.
- 5 - a process for the preparation of a polypeptide which has methylarginase activity, which process comprises cultivating a host cell harbouring an expression vector of the invention under conditions to provide for expression of the said polypeptide, and recovering the expressed polypeptide.
- 10 - a modulator of methylarginase activity.
- a method for identifying a modulator of methylarginase activity and/or expression, comprising:
 - (i) contacting a polynucleotide of the invention, a polypeptide of the invention, a vector of the invention or a cell of the invention and a test substance under conditions that would
15 permit methylarginase activity in the absence of the test substance; and
 - (ii) determining thereby whether the said substance modulates the activity and/or expression of methylarginase.
- 20 - a modulator of methylarginase activity and/or expression identified by the method of the method of the invention.
- a polynucleotide, a polypeptide, an expression vector or a modulator of the invention for use in a method of treatment of the human or animal body by therapy.
- 25 - use of a polynucleotide, a polypeptide, an expression vector or a modulator which is an activator of the invention for the manufacture of a medicament for use in the treatment of hyperlipidaemia, renal failure, hypertension, restenosis after angioplasty, atherosclerosis, complications of heart failure, schizophrenia, multiple sclerosis or
30 cancer.
- use of a modulator of the invention which is an inhibitor of

methylarginase activity and/or expression for the manufacture of a medicament for use in the treatment of ischaemia-reperfusion injury of the brain or heart, cancer, lethal hypotension in severe inflammatory conditions such as septic shock or multi-organ failure, or local and systemic inflammatory disorders including arthritis, skin disorders, inflammatory cardiac disease or migraine.

- a pharmaceutical composition comprising a polynucleotide, a polypeptide, an expression vector or a modulator which is an activator of the invention and a pharmaceutically acceptable carrier and/or diluent.
- a method of treating a human or animal suffering from hyperlipidaemia, renal failure, hypertension, restenosis after angioplasty, atherosclerosis, complications of heart failure, schizophrenia, multiple sclerosis or cancer, which method comprises administering to the host a therapeutically effective amount of a polypeptide, an expression vector, or a modulator which is an activator of the invention.
- a method of treating a human or animal suffering from ischaemia-reperfusion injury of the brain or heart, cancer, lethal hypotension in severe inflammatory conditions such as septic shock or multi-organ failure, or local and systemic inflammatory disorders including arthritis, skin disorders, inflammatory cardiac disease or migraine, which method comprises administering to the host a therapeutically effective amount of a modulator which is an inhibitor of the invention.
- products containing a modulator which is an inhibitor of the invention and a methylarginine as a combined preparation for simultaneous, separate or sequential use in a method of treatment of ischaemia-reperfusion injury of the brain or heart, cancer, lethal hypotension in severe inflammatory conditions such as septic shock or multi-organ failure, or local and systemic inflammatory disorders including arthritis, skin disorders, inflammatory cardiac disease or migraine

Brief description of the drawings

Figure 1 shows an amino acid alignment of rat and human DDAH I with human DDAHII. The derived amino acid sequences of human and rat DDAH I and human DDAHII were aligned using the clustal programme. Amino acid identities are indicated (*), highly conservative substitutions (:) and conservative substitutions (.).

Figure 2 shows recombinant expression of human DDAH II. Aliquots of *E. coli* transfected with either empty vector (lanes 1 and 3) or vector containing human DDAH II cDNA (lanes 2 and 4) were resolved on 15% SDS-PAGE gels. Gels were either stained for total protein with coomassie blue (lanes 1 and 2) or processed for western blotting (lanes 3 and 4) as described under Experimental Procedures. The filled arrow indicates the ~40kDa recombinant protein that is specifically recognised by the anti-PentaHis antibody. The migration of molecular weight markers is indicated.

Figure 3 shows DDAH activity of recombinant DDAH II. Aliquots of cell lysates of *E. coli* transfected with either empty vector or vector containing human DDAH II cDNA were assayed for DDAH activity as described under Experimental Procedures. Assays were performed in triplicate and the data is expressed as the average of the three replicates after subtraction of background. The data presented is the result of one representative experiment. Similar results were obtained in four independent experiments. The data shown represent the hydrolysis of ~1mmol L-NMMA hr⁻¹ by *E. coli* lysates containing recombinant DDAH II. Under the same conditions, a 30% rat liver homogenate hydrolysed ~18mmol L-NMMA hr⁻¹

Figure 4 shows tissue distribution of human DDAH and NOS isoforms. Labelled probes specific for human DDAH I, DDAH II, neuronal NOS, endothelial NOS and b-actin were sequentially hybridized to a commercially available multiple-tissue northern blot. The migration of molecular weight markers is indicated.

Figure 5 shows alignment of human DDAH I and II with *Pseudomonas* Arginine Deiminase. The derived amino acid of human DDAH I and II were aligned with the amino acid sequence of *Pseudomonas* X arginine deiminase. Amino acid identities are indicated (*), highly conservative substitutions (:), and conservative substitutions (.). Boxed regions indicated motifs highly conserved between arginine deiminases.

Figure 6A shows the alignment using ClustalW of human DDAH I and DDAHs from *S.coelicolor*, *P.aeruginosa* and *M.tuberculosis*. Identical amino acids are indicated by (*), highly conserved amino acid substitutions by (:) and conserved amino acid substitutions by (.).

S. coelicolor DDAH is encoded by residues 33784 to 33011 of cosmid St4C6. The sequence does not have an individual accession number. *P. aeruginosa* DDAH sequence is contained within a contiguous genomic DNA sequence (contig 1281). Again, the sequence does not have an individual accession number. *M. tuberculosis* DDAH has been deposited under accession number DDAH Z797022.

Figure 6B shows a similar alignment using ClustalW of *P.aeruginosa* DDAH and arginine deiminase.

Figure 7 shows enzymatic activity of ScDDAH and PaDDAH. The effect of 10mM ADMA and SDMA on recombinant ScDDAH and paDDAH was studied using the assay conditions described in the material and methods section below. Assays were carried out in triplicate on aliquots of cell lysates containing empty vector, scDDAH cDNA or paDDAH cDNA and data was expressed as a mean of the total number of replicates after subtraction of background. The results shown are the mean of three independent experiments.

Detailed Description of the Invention

Polynucleotides

The invention provides a polynucleotide which:

- (a) encodes a polypeptide that has the properties of a methylarginase, which polynucleotide is selected from:
- (1) the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11;
 - (2) a sequence which hybridises selectively to the complement of a sequence defined in (1); and
 - (3) a sequence that is degenerate as a result of the genetic code with respect to a nucleic sequence defined in (1) or (2); or
- (b) is a sequence complementary to a polynucleotide defined in (a).

SEQ ID NOS: 1, 3, 5, 7, 9 and 11 set out the sequences of human DDAH1, DDAH2, *S. coelicolor* DDAH, *P. aeruginosa* DDAH, *P. aeruginosa* arginine deiminase and *M. tuberculosis* DDAH respectively.

Polynucleotides of the invention also include variants of the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11 which can function as methylarginases. Such variants thus have the ability to catalyze the production of citrulline from methylarginines. Typically a polynucleotide of the invention comprises a contiguous sequence of nucleotides which is capable of hybridizing under selective conditions to the complement of the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11.

A polynucleotide of the invention and the complement of the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11 can hybridize at a level significantly above background. Background hybridization may occur, for example, because of other cDNAs present in a cDNA library. The signal level generated by the interaction between a polynucleotide of the invention and the complement of the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11 is typically at least 10 fold, preferably at least 100 fold, as intense as interactions between other polynucleotides and the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with ³²P. Selective hybridisation may typically be achieved using conditions of low stringency (0.03M sodium chloride and 0.03M sodium citrate at about 40°C), medium stringency (for example, 0.03M sodium chloride and 0.03M sodium citrate at about 50°C) or high stringency (for example, 0.03M sodium chloride and 0.03M sodium

citrate at about 60°C).

A nucleotide sequence which is capable of selectively hybridizing to the complement of the DNA coding sequence of SEQ ID NOS: 1, 3, 5, 7, 9 or 11 will generally have at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11 over a region of at least 20, preferably at least 30, for instance at least 40, at least 60, more preferably at least 100 contiguous nucleotides or most preferably over the full length of SEQ ID NO: 1, 3, 5, 7, 9 or 11.

Any combination of the above mentioned degrees of sequence identity and minimum sizes may be used to define polynucleotides of the invention, with the more stringent combinations (i.e. higher sequence identity over longer lengths) being preferred. Thus, for example a polynucleotide which has at least 90% sequence identity over 25, preferably over 30 nucleotides forms one aspect of the invention, as does a polynucleotide which has at least 95% sequence identity over 40 nucleotides.

The coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11 may be modified by nucleotide substitutions, for example from 1, 2 or 3 to 10, 25, 50 or 100 substitutions.

The polynucleotide of SEQ ID NO: 1, 3, 5, 7, 9 or 11 may alternatively or additionally be modified by one or more insertions and/or deletions and/or by an extension at either or both ends. The modified polynucleotide generally encodes a polypeptide which has methylarginase activity. Degenerate substitutions may be made and/or substitutions may be made which would result in a conservative amino acid substitution when the modified sequence is translated, for example as shown in the Table below.

Polynucleotides of the invention may comprise DNA or RNA. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to polynucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the *in vivo* activity or lifespan

of polynucleotides of the invention.

Polynucleotides of the invention may be used as a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labeled with a revealing label by conventional means using radioactive or non-radioactive labels, or
5 the polynucleotides may be cloned into vectors.

Such primers, probes and other fragments will preferably be at least 10, preferably at least 15 or at least 20, for example at least 25, at least 30 or at least 40 nucleotides in length. They will typically be up to 40, 50, 60, 70, 100 or 150 nucleotides in length. Probes and fragments can be longer than 150 nucleotides in
10 length, for example up to 200, 300, 400, 500, 600, 700 nucleotides in length, or even up to a few nucleotides, such as five or ten nucleotides, short of the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11.

Polynucleotides such as a DNA polynucleotide and primers according to the invention may be produced recombinantly, synthetically, or by any means available
15 to those of skill in the art. They may also be cloned by standard techniques. The polynucleotides are typically provided in isolated and/or purified form.

In general, primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time.

Techniques for accomplishing this using automated techniques are readily available
20 in the art.

Longer polynucleotides will generally be produced using recombinant means, for example using PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15-30 nucleotides) to a region of the G14 gene which it is desired to clone, bringing the primers into contact with mRNA
25 or cDNA obtained from a human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a
30 suitable cloning vector.

Such techniques may be used to obtain all or part of the DDAHI and DDAHII

genes described herein. Genomic clones corresponding to the cDNA of SEQ ID NOS: 1, 3, 5, 7, 9 or 11 containing, for example, introns and promoter regions are also aspects of the invention and may also be produced using recombinant means, for example using PCR (polymerase chain reaction) cloning techniques, starting with
5 genomic DNA from for example a bacterial, an animal or a human cell.

Although in general the techniques mentioned herein are well known in the art, reference may be made in particular to Sambrook *et al*, 1989, Molecular Cloning: a laboratory manual.

Polynucleotides which do not have 100% sequence identity to the sequence
10 of SEQ ID NOS: 1, 3, 5, 7, 9 or 11 but fall within the scope of the invention can be obtained in a number of ways:

1. Other human allelic variants of the human DDAHI and DDAHII sequences given in SEQ ID NOS: 1 and 3 may be obtained for example by probing
15 genomic DNA libraries made from a range of individuals, for example individuals from different populations, or individuals with different types of disorder related to aberrant NO metabolism, using probes as described above.

In addition, homologues of SEQ ID NO: 1, 3, 5, 7, 9 or 11 may be obtained from other animals particularly mammals (for example mice and rabbits) or fish (for
20 example *Fugu*) or insects (for example *D. melanogaster*) or other invertebrates (for example *C. elegans*), plants (for example *A. thaliana*), bacteria and yeasts and such homologues and fragments thereof in general will be capable of selectively hybridising to the coding sequence of SEQ ID NOS: 1 and 3 or its complement. Such sequences may be obtained by probing cDNA or genomic libraries from
25 dividing cells or tissues or other animal species with probes as described above.

Degenerate probes can be prepared by means known in the art to take into account the possibility of degenerate variation between the DNA sequence of SEQ ID NOS: 1, 3, 5, 7, 9 or 11 and the sequences being probed for under the selective hybridization conditions given above.

2. Allelic variants and species homologues may also be obtained using
30 degenerate PCR which will use primers designed to target sequences within the

variants and homologues encoding likely conserved amino acid sequences. Likely conserved sequences can be predicted from aligning the amino acid sequences of the invention. The primers will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.

3. Alternatively, polynucleotides may be obtained by site directed mutagenesis of SEQ ID NO: 1, 3, 5, 7, 9 or 11 or allelic variants thereof. This may be useful where, for example, silent codon changes are required to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.

The invention further provides double stranded polynucleotides comprising a polynucleotide of the invention and its complement.

Polynucleotides, probes or primers of the invention may carry a revealing label. Suitable labels include radioisotopes such as ^{32}P or ^{35}S , enzyme labels, or other protein labels such as biotin. Such labels may be added to polynucleotides, probes or primers of the invention and may be detected using techniques known *per se*.

Polypeptides

A polypeptide of the invention comprises the amino acid sequence set out in SEQ ID NO: 2, 4, 6, 8, 10 or 12 or a substantially homologous sequence, or a fragment of either said sequence and has methylarginase activity. In general, the naturally occurring amino acid sequence shown in SEQ ID NO: 2, 4, 6, 8, 10 or 12 is preferred.

SEQ ID NOS: 2, 4, 6, 8, 10 and 12 set out the amino acid sequences of human DDAHI, human DDAHII, *S. coelicolor* DDAH, *P.aeruginosa* DDAH, *P.aeruginosa* arginine deiminase and *M.tuberculosis* DDAH respectively.

In particular, a polypeptide of the invention may comprise:

- (a) the polypeptide sequence of SEQ ID NO: 2, 4, 6, 8, 10 or 12;
- (b) an allelic variant or species homologue thereof; or
- (c) a protein with at least 70, at least 80, at least 90, at least 95, at least 98 or at least 99% sequence identity to (a) or (b).

5

An allelic variant will be a variant which will occur naturally, for example, in a human, bacterium or yeast and which will function in a substantially similar manner to the protein of SEQ ID NO: 2, 4, 6, 8, 10 or 12, for example it acts as a methylarginase. Similarly, a species homologue of the protein will be the equivalent

10 protein which occurs naturally in another species and which can function as a methylarginase.

Allelic variants and species homologues can be obtained by following the procedures described herein for the production of the polypeptides of SEQ ID NO: 2, 4, 6, 8, 10 or 12 and performing such procedures on a suitable cell source e.g. a

15 human or bacterium cell. It will also be possible to use a probe as defined above to probe libraries made from human or bacterial cells in order to obtain clones encoding the allelic or species variants. The clones can be manipulated by conventional techniques to generate a polypeptide of the invention which can then be produced by recombinant or synthetic techniques known *per se*.

20

A polypeptide of the invention preferably has at least 60% sequence identity to the protein of SEQ ID NO: 3, more preferably at least 70%, at least 80%, at least 90%, at least 95%, at least 97% or at least 99% sequence identity thereto over a region of at least 20, preferably at least 30, for instance at least 40, at least 60, at least 100 contiguous amino acids or over over the full length of SEQ ID NO: 2, 4, 6, 8, 10

25 or 12.

25

The sequence of the polypeptide of SEQ ID NO: 2, 4, 6, 8, 10 or 12 and of allelic variants and species homologues can thus be modified to provide polypeptides of the invention. Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions. The modified polypeptide generally retains activity as a

30 methylarginase, as defined herein. Conservative substitutions may be made, for example according to the following Table. Amino acids in the same block in the

30

second column and preferably in the same line in the third column may be substituted for each other.

ALIPHATIC	Non-polar	G A P
		I L V
	Polar-uncharged	C S T M
		N Q
	Polar-charged	D E
K R		
AROMATIC		H F W Y

Polypeptides of the invention also include fragments of the above-mentioned full length polypeptides and variants thereof, including fragments of the sequence set out in SEQ ID NO: 2, 4, 6, 8, 10 or 12. Such fragments typically retain activity as a methylarginase.

Other preferred fragments include those which include an epitope. Suitable fragments will be at least 5, e.g. at least 10, at least 12, at least 15 or at least 20 amino acids in size. Epitope fragments may typically be up to 50, 60, 70, 80, 100, 150 or 200 amino acids in size. Polypeptide fragments of the polypeptides of SEQ ID NO: 3, and allelic and species variants thereof may contain one or more (e.g. 1, 2, 3 or 5 to 10, 20 or 30) substitutions, deletions or insertions, including conservative substitutions. Epitopes may be determined by techniques such as peptide scanning techniques already known in the art. These fragments will be useful for obtaining antibodies to polypeptides of the invention.

Polypeptides of the invention may be in a substantially isolated form. It will be understood that the polypeptide may be mixed with carriers or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated. A polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the polypeptide in a preparation in which more than 50%, e.g. more than 80%, 90%, 95% or 99%, by weight of the polypeptide in the preparation is a polypeptide of the invention.

Polypeptides of the invention may be chemically modified, e.g. post-translationally modified. For example, they may be glycosylated or comprise modified amino acid residues. They may also be modified by the addition of Histidine residues to assist their purification or by the addition of a signal sequence to promote their secretion from a cell. Such modified polypeptides and proteins fall within the scope of the term "polypeptide" of the invention.

Polypeptides of the invention may be modified for example by the addition of Histidine residues or a T7 tag to assist their identification or purification or by the addition of a signal sequence to promote their secretion from a cell where the polypeptide does not naturally contain such a sequence.

Vectors

Polynucleotides of the invention can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus, in a further embodiment, the invention provides a method of making polypeptides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell.

Polynucleotides according to the invention may also be inserted into the vectors described above in an antisense orientation in order to provide for the production of antisense RNA. Antisense RNA or other antisense polynucleotides may also be produced by synthetic means. Such antisense polynucleotides may be used in a method of controlling the levels of methylarginases or their variants or species homologues.

Preferably, a polynucleotide of the invention in a vector is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence, such as a promoter, "operably linked" to a coding sequence is positioned in

such a way that expression of the coding sequence is achieved under conditions compatible with the regulatory sequence.

Vectors of the invention may be transformed into a suitable host cell as described above to provide for expression of a polypeptide of the invention. Thus, in
5 a further aspect the invention provides a process for preparing a polypeptide according to the invention which comprises cultivating a host cell transformed or transfected with an expression vector encoding the polypeptide, and recovering the expressed polypeptide.

The vectors may be for example, plasmid, virus or phage vectors provided
10 with a origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a resistance gene for a fungal vector. Vectors may be used *in vitro*, for example for the production of RNA or used to transfect or
15 transform a host cell, for example, *E. coli*. The vectors may also be adapted to be used *in vivo*, for example in a method of gene therapy.

A further embodiment of the invention provides host cells transformed or transfected with the vectors for the replication and/or expression of polynucleotides of the invention. The cells will be chosen to be compatible with the said vector and
20 may for example bacterial (eg. *E. coli*), yeast, insect or mammalian.

Promoters and other expression regulation signals may be selected to be compatible with the host cell for which expression is designed. For example, yeast promoters include *S. cerevisiae* GAL4 and ADH promoters, *S. pombe nmt1* and *adh* promoter. Mammalian promoters include the metallothionein promoter which can be
25 induced in response to heavy metals such as cadmium. Viral promoters such as the SV40 large T antigen promoter or adenovirus promoters may also be used. All these promoters are readily available in the art.

Mammalian promoters, such as β -actin promoters, may be used. Tissue-specific promoters, in particular endothelial or neuronal cell specific promoters (for
30 example the DDAHI and DDAHII promoters), are especially preferred. Viral promoters may also be used, for example the Moloney murine leukaemia virus long

terminal repeat (MMLV LTR), the rous sarcoma virus (RSV) LTR promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter, adenovirus, HSV promoters (such as the HSV IE promoters), or HPV promoters, particularly the HPV upstream regulatory region (URR). Viral promoters are readily available in the art.

5 The vector may further include sequences flanking the polynucleotide giving rise to antisense RNA which comprise sequences homologous to eukaryotic genomic sequences, preferably mammalian genomic sequences, or viral genomic sequences. This will allow the introduction of the polynucleotides of the invention into the genome of eukaryotic cells or viruses by homologous recombination. In particular, a plasmid vector
10 comprising the expression cassette flanked by viral sequences can be used to prepare a viral vector suitable for delivering the polynucleotides of the invention to a mammalian cell. Other examples of suitable viral vectors include herpes simplex viral vectors (for example as disclosed in WO 98/04726 and WO 98/30707) and retroviruses, including lentiviruses, adenoviruses, adeno-associated viruses and HPV viruses (such as HPV-16 or
15 HPV-18). Gene transfer techniques using these viruses are known to those skilled in the art. Retrovirus vectors for example may be used to stably integrate the polynucleotide giving rise to the antisense RNA into the host genome. Replication-defective adenovirus vectors by contrast remain episomal and therefore allow transient expression.

20 Antibodies

The invention also provides monoclonal or polyclonal antibodies to polypeptides encoded by polynucleotides of the invention, to polypeptides of the invention and to fragments thereof. The invention further provides a process for the production of monoclonal or polyclonal antibodies of the invention.

25 Antibodies of the invention may be antibodies to human polypeptides or fragments thereof. Preferred antibodies are those which are able to discriminate between a DDAHI polypeptide or fragment thereof and a DDAHII polypeptide or fragment thereof, and in particular between the human DDAHI and II polypeptides and fragments thereof.

30 For the purposes of this invention, the term "antibody", unless specified to the contrary, includes fragments of whole antibodies which maintain their binding activity

for a polypeptide encoded by a polynucleotide of the invention, a polypeptide of the invention or a fragment thereof. Such fragments include Fv, F(ab') and F(ab')₂ fragments, as well as single chain antibodies. Furthermore, the antibodies and fragment thereof may be chimeric antibodies, CDR-grafted antibodies or humanised antibodies.

- 5 Antibodies of the invention may be used, *inter alia*, in a method for detecting polypeptides of the invention present in a biological sample which method comprises
- (a) providing an antibody of the invention;
 - (b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and
 - 10 (c) determining whether antibody-antigen complex comprising said antibody is formed.

A sample may be for example a tissue extract. Antibodies of the invention may be bound to a solid support and/or packaged into kits in a suitable container along with suitable reagents, controls, instructions, etc.

- 15 Antibodies of the invention can be produced by any suitable method. Means for preparing and characterising antibodies are well known in the art, see for example Harlow and Lane (1988) "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. For example, an antibody may be produced by raising antibody in a host animal against the whole polypeptide or a fragment thereof,
- 20 for example an antigenic epitope thereof, herein after the "immunogen".

A method for producing a polyclonal antibody comprises immunising a suitable host animal, for example an experimental animal, with the immunogen and isolating immunoglobulins from the serum. The animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified.

- 25 A method for producing a monoclonal antibody comprises immortalising cells which produce the desired antibody. Hybridoma cells may be produced by fusing spleen cells from an inoculated experimental animal with tumour cells (Kohler and Milstein (1975) *Nature* 256, 495-497).

- 30 An immortalized cell producing the desired antibody may be selected by a conventional procedure. The hybridomas may be grown in culture or injected intraperitoneally for formation of ascites fluid or into the blood stream of an allogenic

host or immunocompromised host. Human antibody may be prepared by *in vitro* immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr virus.

For the production of both monoclonal and polyclonal antibodies, the experimental animal is suitably a goat, rabbit, rat or mouse. If desired, the immunogen may be administered as a conjugate in which the immunogen is coupled, for example via a side chain of one of the amino acid residues, to a suitable carrier. The carrier molecule is typically a physiologically acceptable carrier. The antibody obtained may be isolated and, if desired, purified.

Animals

The invention provides a non-human animal which is not capable of expressing or is not capable of expressing an active form of one or more isoforms of methylarginase. Preferably the methylarginase isoform is a DDAH I and/or a DDAH II. Typically, the wild-type of the non-human animal will be capable of expressing an active form of the methylarginase which the non-human animal of the invention cannot.

An animal which is not capable of expressing one or more isoforms of methylarginase is one which shows substantially no detectable expression of at least one methylarginase mRNA. An animal which is not capable of expressing an active form of one or more isoforms of methylarginase is one which expresses at least one methylarginase related polypeptide, which polypeptide shows substantially no methylarginase activity.

An animal of the invention may be one in which polynucleotide sequence from a methylarginase encoding gene locus has been deleted or replaced with polynucleotide sequences from another locus or from another organism. Thus, substantially no methylarginase mRNA may be expressed from that methylarginase locus. Alternatively, the coding sequence of a methylarginase gene may have been altered such that the expressed polypeptide shows substantially no methylarginase activity.

Typically a non-human animal of the invention is a so-called "knock-out animal". The term "knock-out animal" is well known to those skilled in the art. Typically, a non-human animal of the invention, for example a knock-out animal, will be a transgenic

animal.

A knock-out animal can be produced according to any suitable method. In general, a polynucleotide construct is produced comprising a marker gene, for example, flanked by genomic sequences. Those genomic sequences correspond to genomic sequences at the methylarginase encoding gene locus of the animal in question. Thus, if the polynucleotide construct is contacted with the methylarginase encoding gene locus of the animal of interest, homologous recombination events may lead to replacement of the chromosomal sequence bordered by the genomic sequences used in the polynucleotide construct with the marker gene. If the marker gene replaces coding sequence or a regulatory sequence, for example a promoter sequence, gene expression and/or activity may be abolished.

The polynucleotide construct is typically transferred into a fertilized egg by pronuclear microinjection so that the contacting described above can occur. Alternative approaches may be used for example, embryonic stem cells or retroviral mediated gene transfer into germ lines. Whichever approach is taken, transgenic animals are then generated. For example, microinjected eggs may be implanted into a host female and the progeny may be screened for the expression of the marker gene. The founder animals that are obtained may be bred.

A non-human animal of the invention may be for example a mammal, preferably a mouse, a reptile, an amphibian, a bird or a fish. Preferred non-human animals are mice. Preferred animals are thus mice in which all or part of the DDAH^I or DDAH^{III} gene locus has been deleted or replaced for example, ie. DDAH^I or DDAH^{III} knock-out mice.

The invention also provides a cell or cell-line derived from a non-human animal of the invention.

The transgenic technology described above is of course equally applicable to the production of non-human animals which over-express one or more isoforms of methylarginase, or express one or more isoforms of methylarginase which have unusually high activities. In such cases the polynucleotide construct used does not replace an endogenous portion of a methylarginase gene with a marker gene. Instead, an endogenous methylarginase gene may be replaced with a polynucleotide construct comprising a promoter, for example one which drives high levels of expression, operably

lined to a methylarginase coding sequence. Alternatively, the construct may comprise a methylarginase promoter sequence operably linked to a reporter gene. It is also possible to produce constructs which do not replace endogenous methylarginase sequences. Use of such constructs will result in animals which contain endogenous methylarginase sequences and the sequences insert by the construct.

The non-human animals described above may be used in the screening assays described below for the identification of modulators of methylarginase activity and/or expression.

10 Assays

The invention provides a method for identifying a modulator of methylarginase activity and/or expression, comprising:

- 15 (i) contacting a polynucleotide according to the invention, a polypeptide according to the invention, a vector according to the invention or a cell according to the invention and a test substance under conditions that would permit methylarginase activity in the absence of the test substance; and
- 20 (ii) determining thereby whether the said substance modulates the activity and/or expression of methylarginase.

Any suitable assay format may be used for identifying a modulator of methylarginase activity and/or expression.

25 In the case of using a polynucleotide or vector of the invention, the assay will typically be carried out on a cell harbouring the polynucleotide or vector or on a cell extract comprising the polynucleotide or vector. The cell or cell extract will typically allow transcription and translation of the polynucleotide or vector in the absence of a test substance.

A typical assay is as follows:

30

- a defined number of cells harbouring a polynucleotide or vector of the

invention are inoculated in growth medium into the wells of a plastics micro-titre plate in the presence of a substance to be tested.

- the micro-titre plates are covered and incubated at an appropriate temperature (eg. 37°C for *E. coli*) in the dark.
- 5 - samples are withdrawn at regular time intervals and assayed for methylarginase activity, as described in the Examples.
- parallel control experiments can be carried out, in which the substance to be tested is omitted.

10 Also, as a control, the samples may be assayed for any other enzyme to exclude the possibility that the test substance is a general inhibitor of gene expression or enzyme activity.

The assay may also be carried out using a polypeptide of the invention, in which any suitable format may be used for identifying a modulator of methylarginase activity.

15 Most preferably such an assay would be carried out in a single well of a plastics microtitre plate, so that high through-put screening for methylarginase activity modulators may be carried out. In practice, the enzyme reaction is commenced by addition of a methylarginase or a substrate for methylarginase. An assay for a methylarginase modulator may therefore be initiated by providing a medium, containing
20 a test substance and one of a methylarginase and a methylarginase substrate. As a control, the progress of the assay can be followed in the absence of the test substance.

Also the substance tested may be tested with any other known polypeptide/enzyme to exclude the possibility that the test substance is a general inhibitor of enzyme activity.

25 Suitable methylarginases for the assay can be obtained using the recombinant techniques described above. Suitable substrates are those comprising asymmetric methylarginines, for example N^Gmonomethyl-L-arginine (L-NMMA), asymmetric dimethylarginine (ADMA). In addition to the methylarginase and a suitable substrate, the reaction mixture can contain a suitable buffer, suitable cofactors and suitable divalent
30 cations as a cofactor. A suitable buffer includes any suitable biological buffer that can provide buffering capability at a pH conducive to the reaction requirements of the

enzyme.

The assay of the invention may be carried out at any temperature at which a methylarginase, in the absence of any inhibitor, is active. Typically, however, the assay will be carried out in the range of from 25°C to 37°C.

5 Measures of enzymatic activity of methylarginase activity are generally known to those skilled in the art, including equilibrium constants, reaction velocities of the appearance of reaction products or the consumption of reaction substrates, reaction kinetics, thermodynamics of reaction, spectrophotometric analysis of reaction products, detection of labelled reaction components, etc. See, generally, Segel, Biochemical
10 Calculations, 2nd Edition, John Wiley and Sons, New York (1976); Suelter, A Practical Guide to Enzymology, John Eiley and Sons, New York (1985). The preferred method of measuring enzymatic activity is by measuring [¹⁴C]citrulline production after the methylarginase has been incubated with [¹⁴C]L-NMMA or [¹⁴C]ADMA.

15 Assays can also be carried out using constructs comprising a a methylarginase gene promoter operably linked to a heterologous coding sequence, to identify compounds which modulate expression of methylarginases at the transcriptional level.

A promoter means a transcriptional promoter. Methylarginase gene promoters can be isolated via methods known to those skilled in the art and as described above. The term "heterologous" indicates that the coding sequence is not operably linked to the
20 promoter in nature; the coding sequence is generally from a different organism to the promoter.

The promoter sequence may be fused directly to a coding sequence or via a linker. The linker sequence may comprise an intron. Excluding the length of any intron sequence, the linker may be composed of up to 45 bases. The linker sequence may
25 comprise a sequence having enhancer characteristics; to boost expression levels.

Preferably the promoter is operably linked to the coding sequence of a reporter polypeptide. The reporter polypeptide may be, for example, the bacterial polypeptide β -glucuronidase (GUS), green fluorescent protein (GFP), luciferase (luc), chloramphenicol transferase (CAT) or β -galactosidase (lacZ).

30 Promoter:reporter gene constructs such as those described above can be incorporated into a recombinant replicable vector. The vector may be used to replicate

the nucleic acid construct in a compatible host cell. The vectors may be, for example, plasmid, virus or phage vectors provided with an origin of replication. Any host cell may be used in which the promoter is functional, but typically the host cell will be a cell of the species from which the promoter derives. The promoter:reporter gene constructs of the invention may be introduced into host cells using conventional techniques.

Thus the invention provides a method for identifying a modulator of methylarginase expression. Typically a promoter:reporter polypeptide construct or a cell harbouring that construct will be contacted with a test substance under conditions that would permit the expression of the reporter polypeptide in the absence of the test substance.

Any reporter polypeptide may be used, but typically GUS or GFP are used. GUS is assayed by measuring the hydrolysis of a suitable substrate, for example 5-bromo-4-chloro-3-indolyl- β -D-glucuronic acid (X-gluc) or 4-methylumbelliferyl- β -glucuronide (MUG). The hydrolysis of MUG yields a product which can be measured fluorometrically. GFP is quantified by measuring fluorescence at 590nm after excitation at 494nm. These methods are well known to those skilled in the art.

Methylarginases

Any methylarginase, for example a methylarginase encoded by a polynucleotide of the invention or a methylarginase having the amino acid sequence of a polypeptide of the invention, may be used in the assays described above. The enzymes may be prokaryotic or eukaryotic. They may be obtained from prokaryotic or eukaryotic extracts, for example from a microbial extract. Alternatively, the enzymes may be produced recombinantly, from, for example, bacteria, yeast or higher eukaryotic cells such as insect cell lines. Preferred methylarginases are a DDAH_I, for example human DDAH_I, or a DDAH_{II}, for example a human DDAH_{II}.

Recombinant expression of human DDAH_{II} and bacterial DDAH_{II} enzymes is described in the Examples.

Test Substances

A substance which modulates the expression or activity of a methylarginase may

do so by binding directly to the relevant gene promoter, thus inhibiting or activating transcription of the gene. Inhibition may occur by preventing the initiation or completion of transcription. Activation may occur, for example, by increasing the affinity of the transcription complex for the promoter. Alternatively a modulator may bind to a protein
5 which is associated with the promoter and is required for transcription.

A substance which modulates the activity of a methylarginase may do so by binding to the enzyme. Such binding may result in activation or inhibition of the protein.

Inhibition may occur, for example if the modulator resembles the substrate and binds at the active site of the methylarginase. The substrate is thus prevented from
10 binding to the same active site and the rate of catalysis is reduced by reducing the proportion of enzyme molecules bound to substrate. A modulator which inhibits the activity of a methylarginase may do so by binding to the substrate. The modulator may itself catalyze a reaction of the substrate, so that the substrate is not available to the enzyme. Alternatively, the inhibitor may simply prevent the substrate binding to the
15 enzyme.

Activation may occur, for example, if the modulator increases the affinity of the substrate for the enzyme or *vice versa*. This means that the proportion of enzyme molecules bound to a substrate is increased and the rate of catalysis will thus increase.

Suitable test substances which can be used in the assays described above include
20 antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and CDR-grafted antibodies) which are specific for a methylarginase or mimics of a methylarginase. In addition, combinatorial libraries, defined chemical identities, peptide and peptide mimetics, oligonucleotides and natural product libraries, such as display libraries (e.g. phage display libraries) may also be
25 tested. The candidate substances may be chemical compounds.

Batches of the test substances may be used in an initial screen of, for example, ten substances per reaction, and the substances of batches which show inhibition tested individually.

30 Modulators

A modulator of methylarginase, for example of a DDAH or an arginine

deiminase, expression and/or activity is one which produces a measurable reduction or increase in methylarginase expression and/or activity in the assays described above. Thus, modulators of methylarginase expression and/or activity may be inhibitors or activators of methylarginase expression and/or activity. A modulator of a methylarginase may be a modulator of a DDAHII or a DDAHIII.

Preferred inhibitors are those which inhibit methylarginase expression and/or activity by at least 10%, at least 20%, at least 30%, at least 40% at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 99% at a concentration of the inhibitor of $1\mu\text{g ml}^{-1}$, $10\mu\text{g ml}^{-1}$, $100\mu\text{g ml}^{-1}$, $500\mu\text{g ml}^{-1}$, 1mg ml^{-1} , 10mg ml^{-1} , 100mg ml^{-1} .

Preferred activators are those which activate methylarginase expression and/or activity by at least 10%, at least 25%, at least 50%, at least 100%, at least, 200%, at least 500% or at least 1000% at a concentration of the activator $1\mu\text{g ml}^{-1}$, $10\mu\text{g ml}^{-1}$, $100\mu\text{g ml}^{-1}$, $500\mu\text{g ml}^{-1}$, 1mg ml^{-1} , 10mg ml^{-1} , 100mg ml^{-1} .

The percentage inhibition or activation represents the percentage decrease or increase in expression/activity in a comparison of assays in the presence and absence of the test substance. Any combination of the above mentioned degrees of percentage inhibition or activation and concentration of inhibitor or activator may be used to define an inhibitor or activator of the invention, with greater inhibition or activation at lower concentrations being preferred.

Candidate substances which show activity in assays such as those described above can be tested in *in vivo* systems, an animal model. Candidate inhibitors could be tested for their ability to increase ADMA and L-NMMA levels and/or to increase blood pressure and/or to decrease endothelium-dependent relaxation of blood vessels.

Candidate activators could be tested for their ability to increase nitric oxide generation as assessed by NO_x measurement and/or to decrease levels of ADMA and L-NMMA. Ultimately such substances would be tested in animal models of the target disease states.

Therapeutic use

Polynucleotides, peptides, expression vectors and modulators of methylarginase

activity and/or expression and modulators of methylarginase activity and/or expression identified by the methods of the invention may be used for the treatment of a condition in which the abnormal metabolism of NO is implicated.

5 Polynucleotides, peptides, expression vectors and activators of methylarginase activity and/or expression may be used in the treatment of conditions in which reduced NO production is implicated. In particular such conditions as hyperlipidaemia, renal failure, hypertension, restenosis after angioplasty, complications of heart failure, or atherosclerosis and its complications may be treated and patients with schizophrenia, multiple sclerosis or cancer may also be treated.

10 Modulators which are inhibitors of methylarginase activity and/or expression may be used in the treatment of conditions in which increased NO production is implicated. In particular conditions such as ischaemia-reperfusion injury of the brain or heart, cancer, lethal hypotension in severe inflammatory conditions such as septic shock or multi-organ failure, or local and systemic inflammatory disorders including arthritis,
15 skin disorders, inflammatory cardiac disease or migraine may be treated.

Alternatively an inhibitor of methylarginase activity and/or expression could be used as a joint therapy together with an inhibitor of NOS activity (for example, a methylarginine). For example, a specific inhibitor of a DDAH isoform could be used with the methylarginine L-NMMA. This approach may radically alter the activity profile
20 of L-NMMA and may result in L-NMMA having an increased inhibitory effect for a specific NOS isoform. Thus, the invention provides products containing an inhibitor of methylarginase activity and/or expression and a methylarginine as a combined preparation for simultaneous, separate or sequential use in the treatment of ischaemia-reperfusion injury of the brain or heart, cancer, lethal hypotension in severe inflammatory
25 conditions such as septic shock or multi-organ failure, or local and systemic inflammatory disorders including arthritis, skin disorders, inflammatory cardiac disease or migraine.

Inhibitors of methylarginase expression and/or activity may also be used as antimicrobial, for example antibacterial, agents. Thus, inhibitors of microbial, for
30 example bacterial, DDAH and arginine deiminase expression and/or activity are useful as antimicrobial agents. Therefore, the invention also provides an inhibitor of a bacterial

methylarginase, for example a DDAH or an arginine deiminase, for use in the treatment of a bacterial infection.

A modulator of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The modulators may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The modulators may also be administered as suppositories. A physician will be able to determine the required route of administration for each particular patient.

The formulation of a modulator for use in preventing or treating the conditions described above will depend upon factors such as the nature of the exact inhibitor, whether a pharmaceutical or veterinary use is intended, etc. An modulator may be formulated for simultaneous, separate or sequential use.

An modulator is typically formulated for administration in the present invention with a pharmaceutically acceptable carrier or diluent. The pharmaceutical carrier or diluent may be, for example, an isotonic solution. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, gum arabic, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.

Liquid dispersions for oral administration may be syrups, emulsions or suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl

alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

5 Solutions for intravenous administration or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

 A therapeutically effective amount of a modulator is administered to a patient. The dose of a modulator may be determined according to various parameters, especially
10 according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular patient. A typical daily dose is from about 0.1 to 50 mg per kg of body weight, according to the activity of the specific modulator, the age, weight and conditions of the subject to be
15 treated, the type and severity of the degeneration and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g.

 The invention potentially allows for the specific regulation of expression and/or activity of a particular isoform of NOS. Substances which have effects specific for one particular methylarginase isoform, for example a DDAH^I or a DDAH^{III}, may be
20 administered non-specifically as they will only modulate the expression or activity of a particular methylarginase and thus the activity of one particular isoform of NOS.

 Some substances may, however, have affect more than one isoform of methylarginase. Such modulators may have to be administered to specific sites, if they are required to regulate only one particular isoform of NOS. For example, if a condition
25 requires the regulation of nNOS the modulator will have to be delivered to neurons. This may be achieved, for example, by delivery via a viral strain such as herpes simplex virus. Viral vectors comprising polynucleotides of the invention are described above. The viral vector delivery method may be used in the case of administration of, for example, polynucleotides of the invention.

30 The polynucleotides and vectors of the invention may be administered directly as a naked nucleic acid construct. Uptake of naked nucleic acid constructs by mammalian

cells is enhanced by several known transfection techniques for example those including the use of transfection agents. Example of these agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectamTM and transfectamTM).

5 Typically, nucleic acid constructs are mixed with the transfection agent to produce a composition. Preferably the naked nucleic acid construct, viral vector comprising the polynucleotide or composition is combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline.
10 The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, or transdermal administration.

The pharmaceutical composition is administered in such a way that the polynucleotide of the invention, viral vector for gene therapy, can be incorporated into cells at an appropriate area. When the polynucleotide of the invention is delivered to
15 cells by a viral vector, the amount of virus administered is in the range of from 10^6 to 10^{10} pfu, preferably from 10^7 to 10^9 pfu, more preferably about 10^8 pfu for adenoviral vectors. When injected, typically 1-2 ml of virus in a pharmaceutically acceptable suitable carrier or diluent is administered. When the polynucleotide of the invention is administered as a naked nucleic acid, the amount of nucleic acid administered is
20 typically in the range of from 1 μ g to 10 mg.

Where the polynucleotide giving rise to the product is under the control of an inducible promoter, it may only be necessary to induce gene expression for the duration of the treatment. Once the condition has been treated, the inducer is removed and expression of the polypeptide of the invention ceases. This will clearly have clinical
25 advantages. Such a system may, for example, involve administering the antibiotic tetracycline, to activate gene expression via its effect on the tet repressor/VP16 fusion protein.

The use of tissue-specific promoters will be of assistance in the treatment of disease using the polypeptides, polynucleotide and vectors of the invention. It will be
30 advantageous to be able express therapeutic genes in only the relevant affected cell types, especially where such genes are toxic when expressed in other cell types.

The routes of administration and dosages described above are intended only as a guide since a skilled physician will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.

5 The invention is illustrated by the following Example:

Example

Materials and methods

Unless otherwise indicated, the methods used are standard biochemistry and molecular biology techniques. Examples of suitable methodology textbooks include Sambrook et al., Molecular Cloning, A Laboratory Manual (1989) and Ausubel et al., Current Protocols in Molecular Biology (1995), John Wiley and Sons, Inc.

Database searching and cDNA cloning

15 The cDNA sequence of human DDAH1 was obtained by a combination of database searching, specific RT-PCR and 5'/3' RACE. The database of expressed sequence tags (dbEST) was searched with the cDNA sequence corresponding to the open reading frame of rat DDAH1 (Kimoto, M., Sasakawa, T., Tsuji, H., Miyatake, S., Oka, T., Nio, N. and Ogawa, T., 1997, *Biochim. Biophys. Acta* **1337**, 6-10) using the 'blast' programme. This search identified a single human cDNA sequence that comprised 20 161bp of human DDAH1 cDNA fused downstream of 160bp of unknown sequence. Using this sequence, two human DDAH1 specific oligonucleotide primers HDDAHL.1 and HDDAHL.2 were designed. Human kidney polyA+ RNA was reverse transcribed from an oligo dT primer, following which human DDAH1 cDNA was PCR amplified in 25 two PCR reactions incorporating either HDDAHL.1 and RDDAHL.1 or HDDAHL.2 and RDDAHL.2. In order to determine the sequence of the 5' and 3' ends of the human DDAH1 open reading frame 5' and 3' RACE was performed. For 5' RACE human kidney polyA mRNA was reverse transcribed using primer HDDAHL.3. Following reverse transcription, RNA was digested with RNase H and cDNA purified using a 30 HighPure DNA purification kit (Boehringer). Purified cDNA was polyA tailed by incubation with terminal transferase in the presence of dATP. Tailed cDNA was used

directly in PCR reactions incorporating OligodTAnchor and HDDADI.4. For 3' RACE human polyA+ RNA was primed with OligodTAnchor and reverse transcribed prior to PCR with oligos HDDAHI.5 and Anchor. All PCR products were cloned into pCRTOP02.1 (In Vitrogen) following the manufactures instructions. CDNA inserts were sequenced using a T7 sequences kit (Amersham) according to the manufacturers instructions.

The sequence of human DDAHII was obtained by data base searching. The database of translated EMBL open reading frames (trembl) was searched with the rat DDAHI peptide sequence. This search identified a hypothetical mouse open reading frame (accession number O08972) that has the capacity to encode a protein of 228 amino acids with 63% similarity to rat DDAHI. Interogation of dbEST with the nucleotide sequence encoding the hypothetical mouse protein identified numerous overlapping human EST's which contained an open reading frame of 858bp with the potential to encode a 285 amino acid protein that is 52% identical to human DDAHI. The oligonucleotides used in these experiments are shown in Table 1.

Table 1. Oligonucleotides used.

	Name	Sequence	Details
20	HDDAHI.1	GGT TGA CAT GAT GAA AGA AGC	Homologous to nucleotides 303-324 of human DDAHI
	HDDAHI.2	CAG CAC CCC GTT GAT TTG TC	Homologous to nucleotides 454-435 of human DDAHI
25	HDDAHI.3	GCT TCT TTC ATC ATG TCA ACC	Homologous to nucleotides 324-303 of human DDAHI
30	HDDAHI.4	CCC AAC AAA GGG CAC GTC TTG	Homologous to nucleotides 682-703 of human DDAHI
	HDDAHII.1	GAT CGA ATT CAG GAT GGG GAC GCC GGG G	Homologous to nucleotides -2-15 of human DDAHII encoding an upstream EcoRI site
35	HDDAHII.2	GAC TTC TAG AGC TGT GGG GGC GTG TG	Homologous to nucleotides 858-840 of human DDAHII encoding a downstream XbaI site
	HDDAHII.3	CTC AGC TCC CTC TGC TTG GTG	Homologous to nucleotides 813-834 of human

		DDAHII
5	HDDAHII.4	GAG GGA GGA TTC ACC CAG TGG Homologous to nucleotides 1003-1024 of human DDAHII
	RDDAHII.1	TCC GCG GGA TCC ATG GCC GGC CTC Homologous to nucleotides -12-12 of rat DDAHII
	RDDAHII.2	CGC TCG GTC TAG ATC AAG AGT CTG TCT T Homologous to nucleotides 872-844 of rat DDAHII
10	HNNOS.1	CTG CTG ATG TCC TCA AAG CCA TCC Homologous to nucleotides 4079-4102 of human nNOS
	HNNOS.2	TCT GTC CCG CGC TTA CAA ACT TGC Homologous to nucleotides 4353-4330 of human nNOS
15	HENOS.1	CAA CCA ACG TCC TGC AGA CCG TGC Homologous to nucleotides 3379-3402 of human eNOS
20	HENOS.2	GGC GGA CCT GAG TCG GGC AGC CGC Homologous to nucleotides 3690-3667 of human eNOS
	Oligo d(T) Anchor	GAC CAC GCG TAT CGA TGT CGA CTT TTT TTT TTT TTT TTV 5'/3' RACE oligo d(T) anchor primer
25	Anchor	GAC CAC GCG TAT CGA TGT CGA C 5'/3' RACE anchor primer

Recombinant expression

The entire human DDAHII open reading frame was PCR amplified from oligo dT primed human kidney cDNA using oligos HDDAHII.1 and HDDAHII.2. Oligo HDDAH II.1 is complementary to base pairs 2-15 of the human DDAHII cDNA and contains an *EcoRI* site in frame with the *EcoTI* site of pPROX.HTa (Life Technologies). HDDAHII.2 is complementary to base pairs 858-840 of the human DDAHII cDNA and contains an artificial *XbaI* site. PCR produced a single product of ~850bp which was digested with *EcoRI* and *XbaI*, ligated into *EcoRI* and *XbaI* digested pRPROX.HTa and transformed into competent *E.coli* DH5 α . A positive clone (pPDDAHII) containing an insert of 858bp was identified and the insert sequenced on both strands. For expression of recombinant human DDAHII, *E.coli* were grown in liquid culture at 25°C to an OD₆₀₀ of 0.5-0.6. Expression was then induced by the addition of IPTG to a final concentration of 1mM and incubation continued for a further two hours. Following induction, cells

were collected by centrifugation, weighed and resuspended in ice cold assay buffer (100mM Na₂HPO₄ pH 6.5) at 1g cells/ml. Cells were disrupted by sonication (6 X 10secs, with 10 sec. intervals) and centrifuged at 50,000g to separate soluble material from insoluble cell debris.

5

DDAH Assay

Aliquots of *E.coli* lysates were incubated at 37°C for 60 min. with 250 ml of 100mM Na₂HPO₄ pH 6.5 containing 0.02μCi [¹⁴C]L-NMMA as described previously (MacAllister *et al.*, 1996, Br. J. Pharmacol. **115**, 1001-1004). Following incubation samples were prepared for determination of [¹⁴C] citrulline production by scintillation counting. Reactions were vortexed with 1ml of 50% (w/v) dowex 50X8-400, centrifuged at 10,000g for 5 min and then 500μl of the supernatant was mixed with 5ml of liquid scintillation fluid and the [¹⁴C] content determined.

10

DDAH Assay

Samples were assayed by incubating 100μl of cells lysates with an equal volume of assay mix (100mM Na₂HPO₄ pH 6.5, containing 0.02μCi [¹⁴C] L-NMMA and 100μM cold L-NMMA) at 37°C for 60 min, as previously reported. The samples were then prepared for scintillation counting to measure the production of [¹⁴C] citrulline by adding 400μl of 50% (w/v) Dowex 50X-400 to the reactions, vortexing and centrifugation at 13000g for 2 min. The [¹⁴C] content of 100μl of supernatant in 1ml scintillation fluid was then determined.

15

20

Northern blot analysis

The tissue distribution of human DDAHI, DDAHII, endothelial NOS and neuronal NOS mRNA was determined by hybridization of ³²P-labelled cDNA probes to commercially available northern blot (Clontech, human multiple tissue northern blot). Probes were produced by PCR amplification of oligo dT-primed human kidney polyA+ mRNA using oligonucleotide primer pairs HDDAHI 4 and 5, HDDAHII 3 and 4, HENOS i and 2 and HNNOS 1 and 2. Following PCR reaction products were resolved on 2% agarose gels, isolated from the gel and labelled using a random primed labelling kit (Boehringer) according to the manufacturers instructions. Labelled probes were

25

30

purified on Nick columns (Pharmacia) and hybridized to filters according to the manufacturers instructions.

Database searching for bacterial sequences

The amino acid sequence of human DDAH was added to search the expressed sequence tag database (dbEST). Open reading frames which showed significant similarity to this sequence were identified in *S.coelicolor* (46.5% over 163 amino acids), *P.aeruginosa* (44.3% over 226 amino acids) and *M.tuberculosis* (37.5% over 24 amino acids). The cDNA sequences encoding these putative bacterial DDAHs were then used to design the primers ScDDAH1 and ScDDAH2, PaDDAHs were then used to design the primers ScDDAH1 and ScDDAH2, PaDDAH1 and PaDDAH4, and TbDDAH1 and TbDDAH4. These oligonucleotides PaDEIM2 and PaDEIM3 were designed from the cDNA sequence of *P.aeruginosa* arginine deiminase to amplifying the coding region. Primers TbDDAH1 and TbDDAH4 were designed to amplify an open reading frame from cosmid Y3G12 which was identified through the database search using hDDAH1. The oligonucleotides used in these experiments are shown in Table 2.

Table 2. Oligonucleotides Used.

Name	Sequence	Details
ScDDAH 1	GATCGAATGTGCCCAGCAAGAAG GCCTG	Homologous to -9 to 20 encoding an upstream <i>EcoRI</i> site
ScDDAH 2	GATCTCTAGATCAGTCGTACAGCTC GCGC	Homologous to 732 to 751 encoding a downstream <i>XbaI</i> site
PaDDAH 1	GAATTCATGTTCAAGCACATCATCG	Homologous to 1 to 19 encoding an upstream <i>EcoRI</i> site
PaDDAH 4	AAGCTTCGCCGCGGCATGGTTC	Homologous to 782 to 768 encoding a downstream <i>Hind III</i> site
TbDDAH 1	GAATCCGCAATGTATCAATG G	Homologous to -12 to 4 encoding an upstream <i>EcoRI</i> site
TbDDAH 2	AAGTTCACGACCCCTCAG	Homologous to 1024 to 1011 encoding a downstream <i>Hind III</i> site

PaDEIM 2 GAATTCAGCACGGAAAAACCAAAC

Homologous to 3 to 22 encoding an
upstream *Eco* RI site

PaDEIM 3 AAGCTTGTAGTCGATCGGGTCGC

Homologous to 1257 to 1239 encoding
a downstream *Hind* III site

Polymerase Chain Reaction and cDNA Cloning

Amplification of *S.coelicolar* DDAH from cosmid 4C6 was carried out by PCR using the oligonucleotides ScDDAH1 and ScDDAH2. PCR was carried out on *P.aeruginosa* genomic DNA using the primers PADDAG1 and PADDAG4 to amplify the putative DDAH. The *P.aeruginosa* arginine deiminase was also amplified using the oligonucleotides PaDEIM2 and PaDEIM3. The oligonucleotides TbDDAH1 and TbDDAH4 were used in PCR to amplifying the *M.tuberculosis* DDAH from cosmid Y3G12 DNA.

All PCR products were cloned into pCRTOP02.1 (InVitrogen) following the manufacturer's instructions.

Expression of Recombinant Proteins

The inserts containing the open reading frames of the bacterial DDAHs were excised from the vector using *Eco* RI and *Hind* III, gel purified, ligated into *Eco* RI and *Hind* III digested pProEX.HT and transformed into competent *E.coli* DH5 α . The arginine deiminase was treated as above but was cloned into *Eco*RI and *Hind* III digested pBAD B (InVitrogen).

For expression of the recombinant proteins, a positive clone was picked and grown in liquid media supplemented with 100 μ g/ml ampicillin. *E.coli* were grown at 25°C to an OD₆₀₀ of 0.5-0.6 for the bacterial DDAHs in pProEX.HT, and at 37° for the arginine deiminase in pBAD B. Induction of expression of the bacterial DDAHs was carried out by addition of IPTG to a final concentration of 1mM and a further incubation of 2 hours at 25°C. Expression of the arginine deiminase was induced by adding arabinose to a final concentration of 0.02% (w/v) and incubating for a further 4 hours at 37°C.

After induction, cells were harvested by centrifugation and resuspended to a concentration of 250 mg/ml in assay buffer (100mM Na₂HPO₄, pH6.5). Cells were

disrupted by sonication (6 X 10 secs.) And centrifuged at 18,000g to remove particulate material.

SDS-Polyacrylamide Gel Electrophoresis and Western Blot Analysis

5 SDS-PAGE was performed in Tris/glycine buffer, pH8.3, on 12% (w/v) separating gel with a 3.5% (w/v) stacking gel. Proteins were transferred onto an Immobilon-P membrane (Millipore) at 200A for 30 minutes. Membranes were then blocked in 5% (w/v) milk in phosphate buffered saline with 0.1 Tween 20 (PBST) for 2 hours. The blot was probed with a polyHistidine antibody (Sigma) at a dilution of
10 1:3000 followed by anti-mouse Ig antibody coupled to horseradish peroxide (Amersham) at a dilution of 1:5000 then developed using an ECL chemiluminescence kit (Amersham).

Results

15 *Cloning of human DDAHI and DDAHII*

Using a combination of RT-PCR and RACE, a cDNA encoding the entire open reading frame of human DDAHI was assembled. The 858bp open reading frame is 90% homologous to rat DDAHI ORF (data not shown) and encodes a polypeptide of 285 amino acids that is 95% identical to the rat protein (Figure 1). A search of the 'trembl'
20 data base using the rat DDAHI amino acid sequence identified a mouse open reading frame encoding a protein with 63% homology over 228 amino acids to rat DDAH. Further data base searching identified a human cDNA of 2000bp containing an open reading frame of 858bp with the potential to encode a protein of 285 amino acids (subsequently referred to as DDAHII). This open reading frame was 63% homologous
25 to human DDAHI at the nucleotide level (data not shown) and the predicted protein is 62% similar to human DDAHI at the amino acid level (Figure 1). Like DDAHI, DDAHII appears to be highly conserved across mammalian species with 98% homology between murine and human DDAHII amino acid sequences (data not shown).

30 *Recombinant expression of human DDAHII*

An N-terminally 6X His-tagged body of DDAHII was expressed in *E.coli* under

the control of an IPTG inducible promoter. Following induction, a band of ~40kDa (-35kDa human DDAHII + 4kDa 6X His-tag and linker) was apparent in the soluble fraction of cell lysates (Figure 2). The induced protein of ~40kDa is specifically recognised by an anti-His6 antibody confirming its identity as recombinant human DDAHII (Figure 2). In order to establish whether DDAHII is a functional homologue of DDAHI we assayed bacterial cell lysates for DDAH activity. Lysates of cells transfected with empty vector did not metabolise [¹⁴C] L-NMMA. In contrast, lysates of cells expression recombinant DDAHII did metabolise [¹⁴C] L-NMMA (Figure 3). This action was inhibited by the DDAH inhibitor S-2-amino-4(3-methylguanidino) butanoic acid (4124W) [ref] and by competition with a molar excess of cold L-NMMA, ADMA or citrulline. Enzyme activity was unaffected in the presence of a molar excess of cold SDMA.

Tissue distribution of human DDAH and NOS

To determine the tissue distribution of DDAHI and DDAHII messenger RNA and to explore any correlation between DDAH and NOS isoform expression we probed a commercially available human multiple tissue northern blots with labelled cDNA probed specific for each isoform (Figure 4). A DDAHI cDNA probe hybridized to a single band of ~4.4Kb that was highly expressed in kidney, brain, pancreas and liver. Lower level expression was also clearly apparent in skeletal muscle whilst signals from the heart placenta and lung were barely detectably. In contrast, a cDNA probe for DDAHII hybridized to a single band of ~2Kb that was most highly expressed by heart, kidney and placenta. In the case of DDAHII, lower level expression in the brain was barely detectable. A probe specific for nNOS revealed high level expression in skeletal muscle and brain, lower levels in kidney and pancreas with no detectable expression in heart, placenta, lung and liver. Endothelial NOS was highly expressed in placenta and heart with lower levels apparent in skeletal muscle, liver, kidney, pancreas and lung, whilst expression in brain was undetectable. The level of β -actin message in each lane is shown as an indication of mRNA loading.

To extend this analysis of DDAH isoform distribution we have examined the level of DDAH I and II mRNA in 43 adult and 7 fetal tissues by RNA dot blot analysis

using isoform specific probes. This analysis indicated that in the brain DDAHI is expressed at high levels whilst DDAHII is expressed at relatively low levels, with both isoforms being expressed at high levels in the spinal cord. However, in highly vascularised tissues such as the heart, aorta, placenta and lung DDAHII expression clearly predominates over DDAHI. In immune tissues (spleen, thymus, peripheral leukocyte, lymph node and bone marrow) DDAHII expression is clearly apparent whilst DDAHI expression is barely detectable. This distinct pattern of DDAH expression is consistent with the suggestion above that DDAHI predominates in tissues which express high levels of the neuronal isoform of NOS and DDAHII expression is most marked in tissues that also express the endothelial form of NOS.

The chromosomal location of human DDAHI and II

In order to determine the chromosomal location of the human DDAHI and DDAHII genes we employed radiation hybrid mapping and fluorescent *in situ* hybridisation (FISH) techniques. For radiation hybrid mapping we screened the Genebridge 4 Radiation Hybrid DNA Panel (Originators Peter Goodfellow and Jean Weissenbach, obtained from the UK HGMP Resource Centre) using oligonucleotide pairs to amplify nucleotides 47 to 273 of the DDAHI cDNA and nucleotides -16 to -163 of the DDAHII cDNA. The results were submitted to the HGMP RhyME mapper which mapped DDAHI to chromosome 1 (LOD=2.7) and DDAHII to chromosome 6p21-23 (LOD>3). For FISH mapping, a human DDAHI genomic clone (clone no. 2218H15, accession number AQ145822) was identified by a blast search of the GSS database using the human DDAHI cDNA sequence. A genomic clone (clone no. 84h3) containing the human DDAHII gene was isolated by PCR screening of a human genomic PAC library (RPC11, constructed by Pieter de Jong and obtained from the UK HGMP-resource Centre). Clones 2218H15 and 84h3 were used as probes in FISH which localised DDAHI to chromosome 1p22 and DDAHII to chromosome 6p21.3.

Identification of DDAH-related proteins

In order to identify proteins with significant primary sequence homology to DDAHI/II we performed a search of the swissprot data with both the human DDAHI and

DDAHII protein sequences. This search revealed significant homology between both DDAH sequences and the sequences of arginine deiminase enzymes from several microbial species. The highest degree of homology was found with the sequence of arginine deiminase from *Pseudomonas putida* (Accession no. p41142) (Figure 5). The homology was strongest within a 69 amino acid domain (residues 123 to 191 of DDAHI) where the identity rises to 22% and the similarity to 70%. In this domain, DDAHI and DDAHII are 80% identical. Comparison of the sequences of human DDAHI and DDAHII with other arginine-utilizing or arginine-producing enzymes, such as peptidyl-arginine deiminase, arginase, argininosuccinate lyase, arginine decarboxylase and nitric oxide synthase revealed no significant amino acid homology.

Cloning of Streptomyces and Pseudomonas DDAH

A ClustalW alignment of the DDAHs from *S. coelicolor*, *P. aeruginosa*, *M. tuberculosis* and human DDAHI amino acid sequences is shown in Figure 6A.

Alignments of *P. aeruginosa* DDAH and arginine deiminase are also shown in Fig. 6B.

Oligonucleotides ScDDAH 1 and ScDDAH 2 were designed from the open reading frame of a putative *S. coelicolor* DDAH identified through database screening. These primers gave a PCR product of approximately 850bp. The primers PaDDAH 1 and PaDDAH 4 amplified a product of approximately 780bp from *P. aeruginosa* genomic DNA and TbDDAH 1 and TbDDAH 4 gave a PCR product of approximately 1150bp from the cosmid Y3G12.

Expression of Recombinant Bacterial DDAHs

Expression of N-terminally 6X His-tagged forms of *S. coelicolor*, *M. tuberculosis* and *P. aeruginosa* DDAH was carried out in *E. coli* under the control of an IPTG inducible promoter. Following induction, a band of ~36kDa was observed in *S. coelicolor* (~32kDa *S. coelicolor* DDAH + ~4kDa 6X His-tag) cell lysates and of 33kDa in *P. aeruginosa* (29kDa *P. aeruginosa* DDAH + ~4kDa 6X His-tag) cell lysates. A polyHistidine antibody specifically recognized these bands providing confirmation of the identity of these proteins as recombinant *S. coelicolor* and *P. aeruginosa* DDAH respectively.

Activity of Recombinant Bacterial DDAH proteins

The bacterial DDAH cell lysates were assayed for DDAH activity to determine whether they were functional homologues of human DDAH I. These were found to metabolize [14C] L-NMMA, as shown in Figure 7. Empty vector was also transfected into cells and the lysates from these were found not to metabolize [14C] L-NMMA. *P. aeruginosa* DDAH showed higher activity compared to that of *S. coelicolor* DDAH.

ADMA and SDMA were both found to compete with L-NMMA as substrates for the bacterial DDAHs (Fig. 7) with ADMA showing a greater effect than SDMA on the metabolism of L-NMMA. Similar results have been obtained for DDAH from *M.tuberculosis*.

CLAIMS

add a' >

1. A polynucleotide which:
 - 5 (a) encodes a polypeptide that has the properties of a methylarginase, which polynucleotide is selected from:
 - (1) the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11;
 - (2) a sequence which hybridises selectively to the complement of a sequence defined in (1); and
 - 10 (3) a sequence that is degenerate as a result of the genetic code with respect to a sequence defined in (1) or (2); or
 - (b) is a sequence complementary to a polynucleotide defined in (a).
2. A polynucleotide according to claim 1 which is a DNA sequence.
- 15 3. A polynucleotide according to claim 1 or 2 which encodes the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10 or 12.
4. A polynucleotide which comprises the coding sequence of SEQ ID NO: 1, 3, 5, 7, 9 or 11 or a fragment thereof.
5. A polypeptide which has methylarginase activity and which comprises
20 the sequence set out in SEQ ID NO: 2, 4, 6, 8, 10 or 12, a sequence substantially homologous thereto or a fragment of either said sequence.
6. A vector incorporating a polynucleotide as defined in any one of claims 1 to 4.
7. A vector according to claim 6, which is an expression vector.
- 25 8. A cell harbouring a polynucleotide according to any one of claims 4, a peptide according to claim 5 or vector according to claim 6 or 7.
9. A process for the preparation of a polypeptide which has methylarginase activity, which process comprises cultivating a host cell harbouring an expression vector according to claim 7 under conditions to provide for expression of the said polypeptide,
30 and recovering the expressed polypeptide.
10. An antibody capable of binding a polypeptide encoded by a

polynucleotide according to any of claims 1 to 4 or a polypeptide according to claim 5.

11. A non-human animal which is not capable of expressing or is not capable of expressing an active form of one or more isoforms of methylarginase.

5 12. A non-human animal according to claim 11 wherein the methylarginase isoform is a dimethylarginine dimethylaminohydroase I (DDAHI).

13. A non-human animal according to claim 11 or 12 wherein the methylarginase isoform is a dimethylarginine dimethylaminohydroase II (DDAHII).

14. A non-human animal according to any one of claims 11 to 13 which is a transgenic animal.

10 15. A non-human animal according to any one of claims 11 to 14 which is a mouse.

16. A modulator of methylarginase activity and/or expression.

17. A modulator according to claim 16, wherein the methylarginase is a DDAHI.

15 18. A modulator according to claim 16, wherein the methylarginase is a DDAHII.

19. A modulator according to any one of claims 16 to 18, which is an inhibitor of methylarginase activity and/or expression.

20 20. A modulator according to any one of claims 16 to 18, which is an activator of methylarginase activity and/or expression.

21. A method for identifying a modulator of methylarginase activity and/or expression, comprising:

25 (i) contacting a polynucleotide according to any one of claims 1 to 4, a polypeptide according to claim 5, a vector according to claim 7 or a cell according to claim 8 and a

test substance under conditions that would permit methylarginase activity in the absence of the test substance; and

30 (ii) determining thereby whether the said substance modulates the activity and/or expression of methylarginase.

22. A modulator of methylarginase activity and/or expression identified by

the method of claim 21.

23. A modulator according to claim 22, wherein the methylarginase is a DDAH1.

24. A modulator according to claims 22, wherein the methylarginase is a DDAHII.

25. A modulator according to any one of claims 22 to 24, which is an inhibitor of methylarginase activity and/or expression.

26. A modulator according to any one of claims 22 to 24, which is an activator of methylarginase activity and/or expression.

27. A polynucleotide according to any one of claims 1 to 4, a polypeptide according to claim 5, an expression vector according to claim 7 or a modulator according to any one of claims 16 to 20 or 22 to 26 for use in a method of treatment of the human or animal body by therapy.

28. A polynucleotide according to any one of claims 1 to 4, a polypeptide according to claim 5, an expression vector according to claim 7 or a modulator according to claim 20 or 26 for use in a method of treatment of hyperlipidaemia, renal failure, hypertension, restenosis after angioplasty, atherosclerosis, complications of heart failure, schizophrenia, multiple sclerosis or cancer.

29. A modulator according to claim 19 or 25 for use in a method of treatment of ischaemia-reperfusion injury of the brain or heart, cancer, lethal hypotension in severe inflammatory conditions such as septic shock or multi-organ failure, or local and systemic inflammatory disorders including arthritis, skin disorders, inflammatory cardiac disease or migraine.

30. Use of a polynucleotide according to any one of claims 1 to 4, a polypeptide according to claim 5, an expression vector according to claim 7 or a modulator according to claim 20 or 26 for the manufacture of a medicament for use in the treatment of hyperlipidaemia, renal failure, hypertension, restenosis after angioplasty, atherosclerosis, complications of heart failure, schizophrenia, multiple sclerosis or cancer.

31. Use of a modulator according to claim 19 or 25 for the manufacture of a medicament for use in the treatment of ischaemia-reperfusion injury of the brain or heart, cancer, lethal hypotension in severe inflammatory conditions such as septic shock or

multi-organ failure, or local and systemic inflammatory disorders including arthritis, skin disorders, inflammatory cardiac disease or migraine.

32. A pharmaceutical composition comprising a polynucleotide according to any one of claims 1 to 4, a polypeptide according to claim 5, an expression vector according to claim 6 or a modulator according to any one of claims 16 to 20 and 22 to 26 and a pharmaceutically acceptable carrier and/or diluent.

33. A method of treating a human or animal suffering from hyperlipidaemia, renal failure, hypertension, restenosis after angioplasty, atherosclerosis, complications of heart failure, schizophrenia, multiple sclerosis or cancer, which method comprises administering to the host a therapeutically effective amount of a polypeptide according to claim 5, an expression vector according to claim 7 or a modulator according to claim 20 or 26.

34. A method of treating a human or animal suffering from ischaemia-reperfusion injury of the brain or heart, cancer, lethal hypotension in severe inflammatory conditions such as septic shock or multi-organ failure, or local and systemic inflammatory disorders including arthritis, skin disorders, inflammatory cardiac disease or migraine, which method comprises administering to the host a therapeutically effective amount of a modulator according to any one of claims 19 or 25.

35. A modulator according to claim 29 for use in said method together with a methylarginine.

36. Use according to claim 31 for the manufacture of a medicament for use in said treatment together with a methylarginine.

37. A method according to claim 34, which further comprises administering to the host a methylarginine.

38. Products containing a modulator according to claim 19 or 25 and a methylarginine as a combined preparation for simultaneous, separate or sequential use in a method of treatment of ischaemia-reperfusion injury of the brain or heart, cancer, lethal hypotension in severe inflammatory conditions such as septic shock or multi-organ failure, or local and systemic inflammatory disorders including arthritis, skin disorders, inflammatory cardiac or migraine disease.

39. A modulator according to claim 35, use according to claim 36, a method

according to claim 37 or products according to claim 38, wherein the methylarginine is L-NMMA.

40. A modulator according to claim 19 or 25, which is an inhibitor of a bacterial methylarginase.

5 41. A modulator according to claim 40 for use in a method of treatment of the human or animal body by therapy.

42. A modulator according to claim 41 for use in the treatment of a bacterial infection.

10 43. Use of a modulator according to claim 40 for the manufacture of a medicament for use in the treatment of a microbial infection.

44. A pharmaceutical composition comprising a modulator according to claim 40 and a pharmaceutically acceptable carrier and/or diluent.

15 45. A method of treatment of a host suffering from a bacterial infection, which method comprises administering to the host a therapeutically effective amount of a modulator according to claim 40.

20

25

30

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 9/78, 15/63, C07K 16/40, A01K 67/00, C12Q 1/34, A61P 3/00, 13/00, 9/00, 25/18, 21/00, 19/00		A2	(11) International Publication Number: WO 00/44888 (43) International Publication Date: 3 August 2000 (03.08.00)
(21) International Application Number: PCT/GB00/00226 (22) International Filing Date: 26 January 2000 (26.01.00) (30) Priority Data: 9901705.5 26 January 1999 (26.01.99) GB 9913066.8 4 June 1999 (04.06.99) GB (71) Applicant (for all designated States except US): UNIVERSITY COLLEGE LONDON [GB/GB]; Gower Street, London WC1E 6BT (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): VALLANCE, Patrick, John, Thompson [GB/GB]; St. Martins House, 4th floor, 140 Tottenham Court Road, London W1P 9LN (GB). LEIPER, James, Mitchell [GB/GB]; St. Martins House, 4th floor, 140 Tottenham Court Road, London W1P 9LN (GB). WHITLEY, Guy, St. John [GB/GB]; St. George's Hospital Medical School, Department of Biochemistry and Immunology, Cranmer Terrace, London SW17 0RE (GB). CHARLES, Ian, George [GB/GB]; St. Martins House, 4th floor, 140 Tottenham Court Road, London W1P 9LN (GB).		(74) Agent: WOODS, Geoffrey, Corlett; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: SCREEN METHOD			
(57) Abstract <p>Two dimethylarginine dimethylaminohydrolase (DDAH) genes have been cloned from humans. These genes can be used to screen for inhibitors and activators of activity and/or expression of DDAHs. Inhibitors and activators of activity and/or expression of DDAHs are useful in the treatment of conditions in which abnormal metabolism of nitric oxide is implicated.</p>			

PCT/GB00/00226

1/6

Rat	DDAH	I
Human	DDAH	I
Human	DDAH	II

MAGLSHP--SVFGRATHAVVRAPPESLCRHALRRSQGEEVDFAERAERQHQLYVGVLGSKLG
MAGLGHP--SAFGRATHAVVRALPESLCQHIALRSAGKEEVDVARAERQHQLYVGVLGSKLG
---MGTPGEGLGRCSHALIRGVPESLASGEGAGGLPALDLAKAQREHGVLGKKLRQRLG
.: * . : ** : ** : * . **** . : : * . * : * : * : * * . : **

LQVVQLPADES LPDCVFVEDVAVVCEETALITRPGAPSRRKVEVDDMMKEALEKLQLNIVEM
LQVVQLPADES LPDCVFVEDVAVVCEETALITRPGAPSRRKVEVDDMMKEALEKLQLNIVEM
LQLELPPEESLPGLPLGDTAVIQGDTALITRPSRARRPEVDGVRKALQDLGLRIVEI
::::*****::*.*.*:::*****:::**.*.*:::***.*.*.*:::

KDENATLDGGDVLFTGREFFVGLSKRTNQRAEILADTFKDYAVSTVPVADSLHLKSFC
KDENATLDGGDVLFTGREFFVGLSKRTNQRAEILADTFKDYAVSTVPVADGLHLKSFC
GDENATLDGTDVLFTGREFFVGLSKWTNHRGAIEIVADTFRDFAVSTVPVSGPSHLRLCG

***** :*****:*****:*****:*****:*****:*****:*****:
*****:*****:*****:*****:*****:*****:*****:

MAGPNLIAIGSSSAQKALKIMQQMSDHRYSKLTVPDDMAANCIYLN--IPSKGHVLLHR
MAGPNLIAIGSSSAQKALKIMQQMSDHRYSKLTVPDDIAANCIYLN--IPNKGHVLLHR
MGGPRTVVAGSSDAAQKAVRAMAVLTDHPYASLTLPDDAAADCLFLRPLGVPVFFLLER
* * * : : * * * : : * * * : : * : : * * * : : * * * : : * : : * * * : : *

TPEEYPESAKVYEKLDHLLIPVNSSEMEKVDGLLTCCSVFINKKTD
TPEEYPESAKVYEKLDHMLIPVMSSELEKVDGLLTCCSVLINKKVDS
GGGDLPSQEQALQKLSDVTLVPVSCSELEKAGAGLSSLCLVLSTRPHS
: * : * : * : * : * : * : * : * : * : * : * : * : *

Figure 1

2/6




Figure 2




Figure 3




Figure 4

	Human	DDAHI	NATLDGGD	VLTGR	EFFVGL	SKRTN	QRGAE	ILADT	TFKDY	AVSTV	PVAD	G----	LHLK	SFC	S	MAG	PN	L	I	A	I	G	S	S	E	S	E	S	E			
Human	DDAHI	NATLDGGD	VLTGR	EFFVGL	SKRTN	QRGAE	ILADT	TFKDY	AVSTV	PVAD	G----	LHLK	SFC	S	MAG	PN	L	I	A	I	G	S	S	E	S	E	S	E				
Human	DDAHI	NATLDGTD	VLTGR	EFFVGL	SKWTN	HRGAE	IVADT	TFRDF	AVSTV	PVG	P----	SHLR	GL	CG	M	G	GP	RT	V	V	A	G	S	S	D	A	A					
P.p.	Deim.	NATLEGGD	VMPVG	KGIVL	IGM	GERTSR	HAIG	QAQNL	FEKGA	EKI	IVAGL	PKS	RAA	M	HLD	TV	F	S	F	C	D	R	D	L	V	T	F	P	E	V	V	K

Figure 5

Figure 6B




Figure 7

Nixon & Vanderhye P.C. (6/92)

RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled DIMETHYLARGININE DIMETHYLAMINOHYDROLASES

the specification of which (check applicable box(es)):

☐ is attached hereto

☐ was filed on

☒ was filed as PCT international application No. PCT/GB 00/00226 on 26th January 2000

and (if applicable to U.S. or PCT application) was amended on

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 C.F.R. 1.56(a). I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application.

Prior Foreign Application(s):

Application Number	Country	Day/Month/Year Filed
9901705.5	United Kingdom	26 th January 1999
9913066.8	United Kingdom	4 th June 1999

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56(a) which occurred between the filing date of the prior applications and the national or PCT international filing date of this application.

Prior U.S./PCT Application(s):

Application Serial No.	Day/Month/Year Filed	Status patented, pending, abandoned
PCT/GB 00/00226	26 th January 2000	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Nixon & Vanderhye P.C., 1100 North Glebe Road, 8th Floor, Arlington, Virginia 22201-4714, telephone number (703) 816-400 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Michals, 29009; Duane M. Byers, 33363; Paul J. Henon, 33626; Jeffrey H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnham, Jr., 29366; Thomas E. Byrne, 32205.

1) Inventor's Signature [Signature] Date 26/7/01

Inventor's Name (typed) Patrick John Thompson VALLANCE British
First Middle Initial Family Name Citizenship

Residence (City) LONDON GBX (State/Foreign Country) United Kingdom

Post Office Address UCL Centre for Clinical Pharmacology, The Rayne Institute, 5 University Street, London, United Kingdom
 Zip Code WC1E 6JF

2) Inventor's Signature [Signature] Date 9/8/01

Inventor's Name (typed) Jan George CHARLES British
First Middle Initial Family Name Citizenship

Residence (City) LONDON GBX (State/Foreign Country) United Kingdom

Post Office Address The Wolfson Institute of Biomedical Research, The Cruciform Building, University College London, Gower Street, London, United Kingdom
 Zip Code WC1E 6BT

FOR ADDITIONAL INVENTORS, check box [X] and attach sheet with same information and signature and date for each.

3) Inventor's Signature *[Signature]* Date 27/7/01

Inventor's Name (typed)	James	Mitchell	LEIPER	British
	First	Middle Initial	Family Name	Citizenship

Residence (City) LONDON GBX (State/Foreign Country) United Kingdom

Post Office Address UCL Centre for Clinical Pharmacology The Rayne Institute, 5 University Street, London, United Kingdom
 Zip Code WC1E 6JF

4) Inventor's Signature [Signature] Date 3/8/01

Inventor's Name (typed)	<u>Guy</u> First	<u>St. John</u> Middle Initial	<u>WHITLEY</u> Family Name	<u>British</u> Citizenship
-------------------------	---------------------	-----------------------------------	-------------------------------	-------------------------------

Residence (City) LONDON GBX (State/Foreign Country) United Kingdom

Post Office Address St George's Hospital Medical School, Department of Biochemistry and Immunology, Cranmer Terrace, London
SW17 0RE, United Kingdom Zip Code SW17 0RE

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: UNIVERSITY COLLEGE LONDON

(B) STREET: Gower Street

(C) CITY: London

(E) COUNTRY: United Kingdom

(F) POSTAL CODE (ZIP): WC1E 6BT

(ii) TITLE OF INVENTION: SCREEN METHOD

(iii) NUMBER OF SEQUENCES: 12

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EP0)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 858 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ATGGCCGGCC TCGGCCACCC CTCCGCCTTC GGCCGGGCCA CCCACGCCGT GGTGCGGGCG	60
CTACCCGAGT CGCTCTGCCA GCACGCGCTG AGAAGCGCCA AGGGCGAGGA GGTGGACGTC	120
GCCCGCGCGG AACGGCAGCA CCAGCTCTAC GTGGGCGTGC TGGGCAGCAA GCTGGGGCTG	180
CAGGTGGTGG AGCTGCCGGC CGACGAGAGC CTTCCGGACT GCGTCTTCGT GGAGGACGTG	240
GCCGTGGTGT GCGAGGAGAC GGCCCTCATC ACCCGACCCG GGGCGCCGAG CCGGAGGAAG	300
GAGGTTGACA TGATGAAAGA AGCATTAGAA AACTTCAGC TCAATATAGT AGAGATGAAA	360
GATGAAAATG CAACTTTAGA TGGCGGAGAT GTTTTATTCA CAGGCAGAGA ATTTTTTGTG	420
GGCCTTTCCA AAAGGACAAA TCAACGAGGT GCTGAAATCT TGGTGATAC TTTTAAGGAC	480

TATGCAGTCT CCACAGTGCC AGTGGCAGAT GGGTTGCATT TGAAGAGTTT CTGCAGCATG 540
 GCTGGGCCCTA ACCTGATCGC AATTGGGTCT AGTGAATCTG CACAGAAGGC CCTTAAGATC 600
 ATGCAACAGA TGAGTGACCA CCGCTACGAC AAACCTCACTG TGCCTGATGA CATAGCAGCA 660
 AACTGTATAT ATCTAAATAT CCCCAACAAA GGGCACGTCT TGCTGCACCG AACCCCGGAA 720
 GAGTATCCAG AAAGTGCAAA GGTTTATGAG AAACCTGAAGG ACCATATGCT GATCCCCGTG 780
 AGCATGTCTG AACTGGAAAA GGTGGATGGG CTGCTCACCT GCTGCTCAGT TTTAATTAAC 840
 AAGAAGGTAG ACTCCTGA 858

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 285 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Ala Gly Leu Gly His Pro Ser Ala Phe Gly Arg Ala Thr His Ala
 1 5 10 15
 Val Val Arg Ala Leu Pro Glu Ser Leu Cys Gln His Ala Leu Arg Ser
 20 25 30
 Ala Lys Gly Glu Glu Val Asp Val Ala Arg Ala Glu Arg Gln His Gln
 35 40 45
 Leu Tyr Val Gly Val Leu Gly Ser Lys Leu Gly Leu Gln Val Val Glu
 50 55 60
 Leu Pro Ala Asp Glu Ser Leu Pro Asp Cys Val Phe Val Glu Asp Val
 65 70 75 80
 Ala Val Val Cys Glu Glu Thr Ala Leu Ile Thr Arg Pro Gly Ala Pro
 85 90 95
 Ser Arg Arg Lys Glu Val Asp Met Met Lys Glu Ala Leu Glu Lys Leu
 100 105 110
 Gln Leu Asn Ile Val Glu Met Lys Asp Glu Asn Ala Thr Leu Asp Gly
 115 120 125

Gly Asp Val Leu Phe Thr Gly Arg Glu Phe Phe Val Gly Leu Ser Lys
130 135 140

Arg Thr Asn Gln Arg Gly Ala Glu Ile Leu Ala Asp Thr Phe Lys Asp
145 150 155 160

Tyr Ala Val Ser Thr Val Pro Val Ala Asp Gly Leu His Leu Lys Ser
165 170 175

Phe Cys Ser Met Ala Gly Pro Asn Leu Ile Ala Ile Gly Ser Ser Glu
180 185 190

Ser Ala Gln Lys Ala Leu Lys Ile Met Gln Gln Met Ser Asp His Arg
195 200 205

Tyr Asp Lys Leu Thr Val Pro Asp Asp Ile Ala Ala Asn Cys Ile Tyr
210 215 220

Leu Asn Ile Pro Asn Lys Gly His Val Leu Leu His Arg Thr Pro Glu
225 230 235 240

Glu Tyr Pro Glu Ser Ala Lys Val Tyr Glu Lys Leu Lys Asp His Met
245 250 255

Leu Ile Pro Val Ser Met Ser Glu Leu Glu Lys Val Asp Gly Leu Leu
260 265 270

Thr Cys Cys Ser Val Leu Ile Asn Lys Lys Val Asp Ser
275 280 285

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 858 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

ATGGGGACGC CGGGGAGGG GCTGGGCCGC TGCTCCCATG CCCTGATCCG GGGAGTCCCA	60
GAGAGCCTGG CGTCGGGGGA AGGTGCGGGG GCTGGCCTTC CCGCTCTGGA TCTGGCCAAA	120
GCTCAAAGGG AGCACGGGGT GCTGGGAGGT AACTGAGGC AACGACTGGG GCTACAGCTG	180
CTAGAACTGC CACCTGAGGA GTCATTGCCG CTGGGACCGC TGCTTGGCGA CACGGCCGTG	240
ATCCAAGGGG ACACGGCCCT AATCACGCGG CCCTGGAGCC CCGCTCGTAG GCCAGAGGTC	300

Arg Pro Glu Val Asp Gly Val Arg Lys Ala Leu Gln Asp Leu Gly Leu

100	105	110
Arg Ile Val Glu Ile Gly Asp Glu Asn Ala Thr Leu Asp Gly Thr Asp		
115	120	125
Val Leu Phe Thr Gly Arg Glu Phe Phe Val Gly Leu Ser Lys Trp Thr		
130	135	140
Asn His Arg Gly Ala Glu Ile Val Ala Asp Thr Phe Arg Asp Phe Ala		
145	150	155
Val Ser Thr Val Pro Val Ser Gly Pro Ser His Leu Arg Gly Leu Cys		
165	170	175
Gly Met Gly Gly Pro Arg Thr Val Val Ala Gly Ser Ser Asp Ala Ala		
180	185	190
Gln Lys Ala Val Arg Ala Met Ala Val Leu Thr Asp His Pro Tyr Ala		
195	200	205
Ser Leu Thr Leu Pro Asp Asp Ala Ala Ala Asp Cys Leu Phe Leu Arg		
210	215	220
Pro Gly Leu Pro Gly Val Pro Pro Phe Leu Leu His Arg Gly Gly Gly		
225	230	235
Asp Leu Pro Asn Ser Gln Glu Ala Leu Gln Lys Leu Ser Asp Val Thr		
245	250	255
Leu Val Pro Val Ser Cys Ser Glu Leu Glu Lys Ala Gly Ala Gly Leu		
260	265	270
Ser Ser Leu Cys Leu Val Leu Ser Thr Arg Pro His Ser		
275	280	285

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 777 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GTGCCCAGCA AGAAGGCCCT GGTCCGCCGC CCCAGCCCCA GGCTCGCCGA AGGACTGGTG

60

WO 00/44888

PCT/GB00/00226

-6-

ACACACGTCG AGCGGGAGCA GGTCGATCAC GGCCTGGCCC TCGAACAGTG GGACGCCTAC 120
 GTCGAGGCCC TCGGAGCACA CGGCTGGGAG ACTCTGGAGG TGGACCCGGC CGAGTACTGT 180
 CCGGACTCGG TCTTCGTCGA GGACGCCGTC GTCGTGTTCC GCAACGTCGC GCTGATCACG 240
 CGGCCCGGCG CCGAGTCGCG GCGCGCGGAG ACGGCCGGCG TCGAGGAGGC CGTGGCCCGG 300
 CTCGGCTGCT CGGTGAACTG GGTGTGGGAG CCGGGCACCC TGGACGGCGG CGACGTCCTG 360
 AAGATCGGCG ACACGATCTA CGTGGGACGC GCGGCCCGGA CCAACGCGGC CGGTGTCCAG 420
 CAGTTGCGGG CGGCGTTCGA GCCGCTGGGC GCCCGGGTCG TCGCCGTGCC CGTGAGCAAG 480
 GTGCTGCATC TGAAGTCGGC GGTCACCGCG CTGCCGGACG GGACGGTGAT CGGGCACATC 540
 CCGCTGACGG ACGTGCCCTC GCTGTTCCCC CGTTTCCTGC CGGTGCCGGA GGAGTCGGGG 600
 GCGCACGTGG TGCTGCTCGG CCGGAGCAGG CTGCTGATGG CGGCGAGCGC GCCAAGACG 660
 GCGGAGCTGC TCGCCGATCT CGGTCACGAG CCGGTGCTCG TCGACATCGG GGAGTTCGAG 720
 AAGCTGGAGG GCTGTGTGAC GTGCCTCTCG GTCAGGCTGC GCGAGCTGTA CGACTGA 777

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 258 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Val Pro Ser Lys Lys Ala Leu Val Arg Arg Pro Ser Pro Arg Leu Ala
 1 5 10 15

Glu Gly Leu Val Thr His Val Glu Arg Glu Gln Val Asp His Gly Leu
 20 25 30

Ala Leu Glu Gln Trp Asp Ala Tyr Val Glu Ala Leu Gly Ala His Gly
 35 40 45

Trp Glu Thr Leu Glu Val Asp Pro Ala Glu Tyr Cys Pro Asp Ser Val
 50 55 60

Phe Val Glu Asp Ala Val Val Val Phe Arg Asn Val Ala Leu Ile Thr

-7-

65 70 75 80
 Arg Pro Gly Ala Glu Ser Arg Arg Ala Glu Thr Ala Gly Val Glu Glu
 85 90 95
 Ala Val Ala Arg Leu Gly Cys Ser Val Asn Trp Val Trp Glu Pro Gly
 100 105 110
 Thr Leu Asp Gly Gly Asp Val Leu Lys Ile Gly Asp Thr Ile Tyr Val
 115 120 125
 Gly Arg Gly Gly Arg Thr Asn Ala Ala Gly Val Gln Gln Leu Arg Ala
 130 135 140
 Ala Phe Glu Pro Leu Gly Ala Arg Val Val Ala Val Pro Val Ser Lys
 145 150 155 160
 Val Leu His Leu Lys Ser Ala Val Thr Ala Leu Pro Asp Gly Thr Val
 165 170 175
 Ile Gly His Ile Pro Leu Thr Asp Val Pro Ser Leu Phe Pro Arg Phe
 180 185 190
 Leu Pro Val Pro Glu Glu Ser Gly Ala His Val Val Leu Leu Gly Gly
 195 200 205
 Ser Arg Leu Leu Met Ala Ala Ser Ala Pro Lys Thr Ala Glu Leu Leu
 210 215 220
 Ala Asp Leu Gly His Glu Pro Val Leu Val Asp Ile Gly Glu Phe Glu
 225 230 235 240
 Lys Leu Glu Gly Cys Val Thr Cys Leu Ser Val Arg Leu Arg Glu Leu
 245 250 255
 Tyr Asp

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 765 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

ATGTTCAAGC ACATCATCGC TCGCAGCCCC GCCCGCAGCC TGGTCGACGG CCTGACCTCC

60

AGCCACCTCG GCAAGCCGGA CTACGCCAAG GCCCTGGAGC AGCACAACGC CTACATCCGC 120
 GCCTTGAGAG CCTGCGACGT GGACATCACC CTGCTGCCGC CGGACGAACG CTTCCCCGAC 180
 TCGGTGTTTCG TCGAGGACCC GGTGCTCTGC ACCTCGCGCT GCGCCATCAT CACCCGCCCC 240
 GCGCCGAAT CGCGGCGCGG CGAGACCGAG ATCATCGAGG AAACCGTGCA GCGCTTCTAT 300
 CCGGGCAAGG TCGAGCGCAT CGAGGCACCC GGCACGGTGG AAGCCGGCGA CATCATGATG 360
 GTCGGCGACC ACTTCTACAT CGGCGAATCG GCGCGACCA ACGCCGAGGG CGCCCGGCAG 420
 ATGATCGCGA TCCTGGAGAA ACATGGCCTC AGCGGCTCGG TGGTGCGCCT GGAAAAGGTC 480
 CTGCACCTGA AGACCGGGCT CGCTACCTG GAACACAACA ACCTGCTGGC CGCCGGCGAG 540
 TTCGTCAGCA AGCCGGAGTT CCAGGACTTC AACATCATCG AGATCCCCGA AGAGGAGTCC 600
 TACGCCGCCA ACTGCATCTG GGTCAACGAA AGGGTGATCA TGCCCGCCGG CTATCCCCGG 660
 ACCCGCGAGA AGATCGCCCG CCTCGGCTAC CGGGTGATCG AGGTGGACAC CTCCGAATAT 720
 CGCAAGATCG ACGGCGGCGT CAGTTGCATG TCGCTGCGCT TCTGA 765

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 254 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Phe Lys His Ile Ile Ala Arg Thr Pro Ala Arg Ser Leu Val Asp
 1 5 10 15

Gly Leu Thr Ser Ser His Leu Gly Lys Pro Asp Tyr Ala Lys Ala Leu
 20 25 30

Glu Gln His Asn Ala Tyr Ile Arg Ala Leu Gln Thr Cys Asp Val Asp
 35 40 45

Ile Thr Leu Leu Pro Pro Asp Glu Arg Phe Pro Asp Ser Val Phe Val
 50 55 60

Glu Asp Pro Val Leu Cys Thr Ser Arg Cys Ala Ile Ile Thr Arg Pro
 65 70 75 80

WO 00/44888

PCT/GB00/00226

-9-

Gly Ala Glu Ser Arg Arg Gly Glu Thr Glu Ile Ile Glu Glu Thr Val
85 90 95

Gln Arg Phe Tyr Pro Gly Lys Val Glu Arg Ile Glu Ala Pro Gly Thr
100 105 110

Val Glu Ala Gly Asp Ile Met Met Val Gly Asp His Phe Tyr Ile Gly
115 120 125

Glu Ser Ala Arg Thr Asn Ala Glu Gly Ala Arg Gln Met Ile Ala Ile
130 135 140

Leu Glu Lys His Gly Leu Ser Gly Ser Val Val Arg Leu Glu Lys Val
145 150 155 160

Leu His Leu Lys Thr Gly Leu Ala Tyr Leu Glu His Asn Asn Leu Leu
165 170 175

Ala Ala Gly Glu Phe Val Ser Lys Pro Glu Phe Gln Asp Phe Asn Ile
180 185 190

Ile Glu Ile Pro Glu Glu Glu Ser Tyr Ala Ala Asn Cys Ile Trp Val
195 200 205

Asn Glu Arg Val Ile Met Pro Ala Gly Tyr Pro Arg Thr Arg Glu Lys
210 215 220

Ile Ala Arg Leu Gly Tyr Arg Val Ile Glu Val Asp Thr Ser Glu Tyr
225 230 235 240

Arg Lys Ile Asp Gly Gly Val Ser Cys Met Ser Leu Arg Phe
245 250

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1257 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

ATGAGCACGG AAAAAACCAA ACTTGGCGTC CACTCCGAAG CCGGCAAACCT GCGCAAAGTG 60

ATGGTCTGCT CGCCCGGACT CGCCACACAG CGCCTGACCC CGAGCAACTG CGACGAGTTG 120

CTGTTGACG ACGTGATCTG GGTGAACCAG GCCAAGCGCG ACCACTTCGA CTTGTCACC 180

AAGATGCGCG AGCGCGGCAT CGACGTCCTC GAGATGCACA ATCTGCTGAC CGAGACCATC	240
CAGAACCCGG AAGCGCTGAA GTGGATCCTC GATCGCAAGA TCACCGCCGA CAGCGTCGGC	300
CTGGGCCTGA CCAGCGAGCT GCGCTCCTGG CTGGAGAGCC TGGAGCCGCG CAAGCTGGCC	360
GAGTACCTGA TCGGCGGCGT CGCCGCTGAC GACCTGCCCG CCAGCGAAGG CGCCAACATC	420
CTCAAGATGT ACCGCGAGTA CCTGGGCCAT TCCAGCTTCC TGCTGCCGCC GTTGCCGAAC	480
ACCCAGTTCA CCCGCGACAC CACTTGCTGG ATCTACGGCG GCGTGACCCT GAACCCGATG	540
TACTGGCCGG CGCGACGACA GGAAACCCTG CTGACCACCG CCATCTACAA GTTCCACCCC	600
GAGTTCGCCA ACGCCGAGTT CGAGATCTGG TACGGCGACC CGGACAAGGA CCACGGCTCC	660
TCGACCCTGG AAGGCGGCGA CGTGATGCCG ATCGGCAACG GCGTGGTCCT GATCGGCATG	720
GGCGAGCGCT CCTCGGCCA GGCCATCGGT CAGGTCGCCC AGTCGCTGTT CGCCAAGGGC	780
GCCGCCGAGC GGGTGATCGT CGCCGGCCTG CCGAAGTCCC GCGCCGCGAT GCACCTGGAC	840
ACCGTGTTCA GCTTCTGCGA CCGCGACCTG GTCACGGTCT TCCCGGAAGT GGTCAAGGAA	900
ATCGTGCCCT TCAGCCTGCG CCCCATCCG AGCAGCCCCT ACGGCATGAA CATCCGCCGC	960
GAGGAGAAAA CCTTCCTCGA AGTGGTCGCC GAATCCCTCG GCCTGAAGAA ACTGCGCGTG	1020
GTCGAGACCG GCGGCAACAG CTTGCGCGCC GAGCGCGAGC AATGGGACGA CGGTAACAAC	1080
GTGGTCTGCC TGGAGCCGGG CGTGGTGGTC GGCTACGACC GCAACACCTA CACCAACACC	1140
CTGCTGCGCA AGGCCGGCGT CGAGGTCATC ACCATCAGCG CCAGCGAACT GGGTCGCGGT	1200
CGCGGCGGCG GCCACTGCAT GACCTGCCCG ATCGTCCGCG ACCCGATCGA CTA CTGA	1257

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 418 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Met	Ser	Thr	Glu	Lys	Thr	Lys	Leu	Gly	Val	His	Ser	Glu	Ala	Gly	Lys
1					5			10					15		

Leu Arg Lys Val Met Val Cys Ser Pro Gly Leu Ala His Gln Arg Leu
 20 25 30
 Thr Pro Ser Asn Cys Asp Glu Leu Leu Phe Asp Asp Val Ile Trp Val
 35 40 45
 Asn Gln Ala Lys Arg Asp His Phe Asp Phe Val Thr Lys Met Arg Glu
 50 55 60
 Arg Gly Ile Asp Val Leu Glu Met His Asn Leu Leu Thr Glu Thr Ile
 65 70 75 80
 Gln Asn Pro Glu Ala Leu Lys Trp Ile Leu Asp Arg Lys Ile Thr Ala
 85 90 95
 Asp Ser Val Gly Leu Gly Leu Thr Ser Glu Leu Arg Ser Trp Leu Glu
 100 105 110
 Ser Leu Glu Pro Arg Lys Leu Ala Glu Tyr Leu Ile Gly Gly Val Ala
 115 120 125
 Ala Asp Asp Leu Pro Ala Ser Glu Gly Ala Asn Ile Leu Lys Met Tyr
 130 135 140
 Arg Glu Tyr Leu Gly His Ser Ser Phe Leu Leu Pro Pro Leu Pro Asn
 145 150 155 160
 Thr Gln Phe Thr Arg Asp Thr Thr Cys Trp Ile Tyr Gly Gly Val Thr
 165 170 175
 Leu Asn Pro Met Tyr Trp Pro Ala Arg Arg Gln Glu Thr Leu Leu Thr
 180 185 190
 Thr Ala Ile Tyr Lys Phe His Pro Glu Phe Ala Asn Ala Glu Phe Glu
 195 200 205
 Ile Trp Tyr Gly Asp Pro Asp Lys Asp His Gly Ser Ser Thr Leu Glu
 210 215 220
 Gly Gly Asp Val Met Pro Ile Gly Asn Gly Val Val Leu Ile Gly Met
 225 230 235 240
 Gly Glu Arg Ser Ser Arg Gln Ala Ile Gly Gln Val Ala Gln Ser Leu
 245 250 255
 Phe Ala Lys Gly Ala Ala Glu Arg Val Ile Val Ala Gly Leu Pro Lys
 260 265 270
 Ser Arg Ala Ala Met His Leu Asp Thr Val Phe Ser Phe Cys Asp Arg
 275 280 285

Asp Leu Val Thr Val Phe Pro Glu Val Val Lys Glu Ile Val Pro Phe
 290 295 300
 Ser Leu Arg Pro Asp Pro Ser Ser Pro Tyr Gly Met Asn Ile Arg Arg
 305 310 315 320
 Glu Glu Lys Thr Phe Leu Glu Val Val Ala Glu Ser Leu Gly Leu Lys
 325 330 335
 Lys Leu Arg Val Val Glu Thr Gly Gly Asn Ser Phe Ala Ala Glu Arg
 340 345 350
 Glu Gln Trp Asp Asp Gly Asn Asn Val Val Cys Leu Glu Pro Gly Val
 355 360 365
 Val Val Gly Tyr Asp Arg Asn Thr Tyr Thr Asn Thr Leu Leu Arg Lys
 370 375 380
 Ala Gly Val Glu Val Ile Thr Ile Ser Ala Ser Glu Leu Gly Arg Gly
 385 390 395 400
 Arg Gly Gly Gly His Cys Met Thr Cys Pro Ile Val Arg Asp Pro Ile
 405 410 415
 Asp Tyr

(2) INFORMATION FOR SEQ ID NO: 11:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1014 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

ATGTATCAAT GGAAAATACG CAACGACCAT CGTTTGATTG TGAAATCAGA GCCAAATATC	60
GTTGGTTTAT GACGGATTCC TACGTCGCTG CTGCCCGTCT AGGGTCACCT GCACGCCGCA	120
CCCCCGGAC GCGGCGGTAT GCAATGACCC CGCCGGCCTT CTTTGCCGTC GCATACGCGA	180
TCAACCCCTG GATGGACGTC ACCGCGCCAG TCGACGTCCA AGTCGCGCAA GCACAGTGGG	240
AGCACCTCCA CCAGACCTAT CTTGGGCTAG GCCACAGCGT GGATCTGATC GAGCCCATT	300
CCGGGTTACC GGACATGGTG TACACGCCA ACGGTGGGTT CATCGCGCAC GACATCGCCG	360

TGGTCGCCCC GTTCCGGTTC CCCGAACGAG CTGGTGAGTC TAGAGCCTAT GCCAGCTGGA 420
 TGTCCTCGGT CGGATATCGC CCGGTGACCA CCCGCCACGT CAACGAGGGA CAGGGCGACC 480
 TGCTGATGGT TGGCGAAAGG GTGTTGGCGG GCTACGGCTT TCGCACAGAC CAGCGCGCAC 540
 ACGCCGAAAT CGCCGCGGTG CTTGGTCTGC CGGTGGTCTC CCTCGAGTTG GTCGACCCAC 600
 GGTTCTATCA CCTGGACACC GCGCTGGCCG TGCTCGACGA CCACACGATC GCCTACTACC 660
 CGCCGGCGTT CAGTACGGCA GCGCAGGAAC AGTTGTGGC GCTGTTCCCC GACGCGATTG 720
 TGGTCGGCAG TGCCGACGCG TTCGTGTTCTG GACTCAACGC CGTCTCTGAC GGTCTGAACG 780
 TAGTGCTTCC GGTGCGGGCC ATGGGTTTTG CGGCGCAGTT ACGCGCAGCC GGCTTCGAGC 840
 CGGTCGGTGT CGATCTGTCC GAGCTGCTCA AGGGCGGCGG TTCCGTCAAG TGCTGCACGC 900
 TGGAGATACA CCCATGACAA ATCTCGCGGA TGCCACTCAG GCCACTATGG CACTGGTCTGA 960
 AAGGCATGCA GCGCACAATT ATTCGCCGCT GCCTGTGGTG GCGGCCAGCG CTGA 1014

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 305 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Asn Val Ser Met Glu Asn Thr Gln Arg Pro Ser Phe Asp Cys Glu Ile
 1 5 10 15

Arg Ala Lys Tyr Arg Trp Phe Met Thr Asp Ser Tyr Val Ala Ala Ala
 20 25 30

Arg Leu Gly Ser Pro Ala Arg Arg Thr Pro Arg Thr Arg Arg Tyr Ala
 35 40 45

Met Thr Pro Pro Ala Phe Phe Ala Val Ala Tyr Ala Ile Asn Pro Trp
 50 55 60

Met Asp Val Thr Ala Pro Val Asp Val Gln Val Ala Gln Ala Gln Trp
 65 70 75 80

Glu His Leu His Gln Thr Tyr Leu Arg Leu Gly His Ser Val Asp Leu
 85 90 95

Ile Glu Pro Ile Ser Gly Leu Pro Asp Met Val Tyr Thr Ala Asn Gly
100 105 110

Gly Phe Ile Ala His Asp Ile Ala Val Val Ala Arg Phe Arg Phe Pro
115 120 125

Glu Arg Ala Gly Glu Ser Arg Ala Tyr Ala Ser Trp Met Ser Ser Val
130 135 140

Gly Tyr Arg Pro Val Thr Thr Arg His Val Asn Glu Gly Gln Gly Asp
145 150 155 160

Leu Leu Met Val Gly Glu Arg Val Leu Ala Gly Tyr Gly Phe Arg Thr
165 170 175

Asp Gln Arg Ala His Ala Glu Ile Ala Ala Val Leu Gly Leu Pro Val
180 185 190

Val Ser Leu Glu Leu Val Asp Pro Arg Phe Tyr His Leu Asp Thr Ala
195 200 205

Leu Ala Val Leu Asp Asp His Thr Ile Ala Tyr Tyr Pro Pro Ala Phe
210 215 220

Ser Thr Ala Ala Gln Glu Gln Leu Ser Ala Leu Phe Pro Asp Ala Ile
225 230 235 240

Val Val Gly Ser Ala Asp Ala Phe Val Phe Gly Leu Asn Ala Val Ser
245 250 255

Asp Gly Leu Asn Val Val Leu Pro Val Ala Ala Met Gly Phe Ala Ala
260 265 270

Gln Leu Arg Ala Ala Gly Phe Glu Pro Val Gly Val Asp Leu Ser Glu
275 280 285

Leu Leu Lys Gly Gly Gly Ser Val Lys Cys Cys Thr Leu Glu Ile His
290 295 300

Pro
305